Breast Cancer: From Transcriptional Control to Clinical Outcome by Jha, Sudhakar et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 23
Breast Cancer: From Transcriptional Control to
Clinical Outcome
Sudhakar Jha, Deepa Rajagopalan,
Shainan Hora and Shweta Pradip Jadhav
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66888
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Clinical Outcome
Sudhakar Jha, Deepa Rajagopalan, 
hainan Hor  and Shwet  Pradip Jadhav
Additional information is available at the end of the chapter
Abstract
Breast cancer is the most common malignancy in women worldwide. The risk of breast 
cancer in women increases with age, and this is partly attributable to the accumula-
tion of genetic lesions. Growing evidence demonstrates the role played by epigene-
tic modifiers and the tumor microenvironment in contributing to the increased risk 
of breast cancer. This chapter provides a comprehensive overview of the epigenetic 
regulatory signatures that impact the well-studied signaling pathways in breast tis-
sues. Additionally, we will also delve into the therapeutic and diagnostic potential of 
noncoding RNAs in breast cancer.
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1. Introduction
Tumorigenesis is a multistep process that involves accumulation of genetic mutations which 
confer a selective growth advantage to the cancer cells. However, an emerging area of research 
suggests that epigenetic changes complement these genetic mutation events and direct the 
cancer cells towards a full blown malignancy [1–3]. Epigenetic changes refer to the modifi-
cations that do not occur on the primary nucleotide sequence of DNA (genetic mutations) 
but rather affect chromatin structure and function and are reversible in nature. Epigenetic 
changes involve histone modifications by enzymes that can “write” marks on histone tails 
such as acetyl and methyl transferases, enzymes that can “erase” these marks such as demeth-
ylases and deacetylases and a group of proteins that can “read” the chromatin marks and 
recruit other proteins to alter gene expression [4].
© 2017 The Author(s). Licensee InTech. This chapter is d stributed under the terms of the Creative Commons
Attribution License (http://creativeco mons.org/licen es/by/3.0), w ich permits unrestricted use,
distribution, and reproduct on in any medium, provided the original work is properly cited.
A recent study in mammary epithelial cells that are on the road to tumorigenic transformation has 
revealed a coordinated series of events that alter DNA methylation and deregulation of histone 
marks across large regions of the chromatin [5], thus underlying the need to study these epigen-
etic modifications to address their diagnostic as well as therapeutic potential in the context of 
breast cancer. Breast cancer is the most common cause of cancer in women worldwide. It is a com-
plex, heterogeneous disease, thus posing a challenge in the diagnosis and treatment of patients. 
At the molecular level, based on the gene signature obtained from cDNA microarrays and global 
mRNA expression studies, breast cancer has been classified into four basic types, namely Luminal 
A, Luminal B, HER2-enriched, and triple negative/basal-like subtype [6–10]. This classification 
is based on the molecular characteristics displayed by the tumor, such as hormone receptor sta-
tus, additional marks such as cytokeratin 5 (CK5) and cell proliferation rate (Ki67 marker1 status; 
summarized in Table 1). These subtypes, along with displaying unique molecular signatures, 
also differ in their prognosis and response to treatments. Apart from the aforementioned mRNA 
markers, recent studies have highlighted the importance of miRNAs in subtyping breast tumors 
as well as providing directions for diagnosis, prognosis and therapy [11, 12].
However, despite several years of study, a broad-spectrum curative therapy for patients with 
malignant breast cancer remains elusive. This chapter will focus on key epigenetic regula-
tors including noncoding RNAs identified in breast cancer that affect the hormonal signaling 
pathways and provide a perspective on combinatorial drug treatments using drugs that tar-
get these epigenetic regulators along with tamoxifen, aromatase inhibitors and other conven-
tional therapeutics in specific sub-types of breast cancer.
1Ki67 marker: Ki67 is a nuclear protein which is used as a marker for proliferation. It is associated with ribosomal RNA 
synthesis and thus serves as a proliferation marker. It is present in all cycling cells (G1, S, G2 and M phase) but it is absent 
in G0 phase cells.
Breast cancer 
molecular subtype
Characteristics Prevalence Treatment response and clinical outcome
Luminal A ER positive and/or PR 
positive
HER-2-negative
Low Ki67
30–70% Hormone therapy, chemotherapy; good prognosis 
and patient survival
Luminal B ER positive and/or PR 
positive
HER-2 positive (or 
HER-2 negative with 
high Ki67)
10–20% Hormone therapy, chemotherapy; fairly high 
survival rates, though not as high as Luminal A
HER-2 ER negative
PR negative
HER-2 positive
10–15% Trastuzumab and anthracycline-based 
chemotherapy; generally poor prognosis
Triple negative/basal/
basal-like
ER negative
PR negative
HER-2 negative
5–15% Platinum-based chemotherapy and PARP 
inhibitors; generally poor prognosis
Table 1. Summary of the common molecular subtypes of breast cancer with their characteristics, disease prevalence and 
treatment response [6].
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2. Epigenetic alterations in breast cancer
Each cell in our body contains the genetic material in the form of DNA, which is the essential 
blueprint required for all cellular functions. DNA is packaged into chromatin by wrapping 
around basic histone proteins to form nucleosomes. These nucleosomes are further con-
densed into the nucleus to form the chromatin by enzymes that catalyze posttranslational 
modifications on the histone tails. The chromatin serves to not only condense the DNA within 
the cellular nucleus but also to control how information in the DNA is retrieved [13]. The 
histone components of the nucleosomes include a pair of H2A-H2B dimers and a tetramer 
of H3 and H4 to form the histone octamer around which the DNA is wound. These core his-
tone proteins undergo a wide variety of posttranslational modifications such as acetylation, 
methylation, ubiquitination, phosphorylation, sumoylation, deamination and ribosylation, to 
name a few [14]. Since histones regulate accessibility of the DNA to transcription factors and 
DNA-modifying enzymes, alterations in the structure and posttranslational modifications of 
histones affects cellular gene expression to a great extent. Enzymes that covalently modify 
histones, acetyltransferases, methyltransferases and kinases, thus regulate multiple cellular 
processes that require accessibility to the DNA such as transcription, DNA replication and 
repair, apoptosis and cell cycle progression [15] (Figure 1). It is thus unsurprising that aber-
rant expression of many epigenetic regulators is prevalent in cancer tissues and contributes 
to the tumorigenesis process. By altering their epigenetic circuitry, cancer cells overcome the 
barrier of replicative senescence, accumulate genomic instability and catapult into an orga-
nized chaos that is the cancer epigenome (Figure 2). This makes it imperative to study the role 
and activity of proteins involved in epigenetic regulation of gene expression in the context of 
tumorigenesis. An important attribute of the chromatin-modifying enzymes is that the reac-
tions catalyzed by these molecules such as histone acetylation are easily reversible and thus 
offer a therapeutic window of opportunity.
Emerging evidence indicates the role played by somatic mutations in the carcinogenesis pro-
cess. A study by Stephens et al. highlighted the significance of these somatic mutations in 
the context of breast cancer [16]. Their study which sequenced the genome of 100 tumors for 
changes in somatic copy numbers and mutations identified point mutations and deletions in 
known cancer-causing “driver” genes characterized in the context of mammary carcinomas 
such as PTEN, BRCA1, TP53, RB1 and AKT1. The highlight however was the identification 
of inactivating somatic mutations in epigenetic regulators such as ARID1B and SMARCD1, 
suggesting an altered epigenetic landscape in these tumors [16]. The reversible nature of epi-
genetic changes and their dynamic role in regulation of cellular gene expression in a tissue 
specific manner makes them potent tumor stimulating factors and reiterates the need to find 
suitable “druggable” epigenetic factors to serve both as a biomarker as well as a therapeutic 
target for the various molecular subtypes of breast cancer [17].
This section will discuss the epigenetic signature, histone posttranslational modifications as 
well as DNA methylation changes, characterized thus far in the various subtypes of breast 
cancer and will provide an overview of targeting these chromatin modifiers as a potential 
combination therapy.
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Figure 2. Altered epigenetic pathways in tumorigenic cells. Schematic depiction of the altered epigenetic landscape in cancer 
cells. Orange nucleosome represents a variant nucleosome which could be introduced as a result of aberrant expression 
and function of chromatin remodelers. Altered expression and function of HATs, HDACs, DNMTs, KMTs and KDMTs 
(represented as different sized icons the figure) results in a widespread disarray of the epigenetic marks in cancer cells.
Figure 1. Epigenetic regulatory circuits in cells. A schematic representation of the epigenetic changes which regulate 
gene expression in normal cells.
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2.1. Histone modifications and histone-modifying enzymes in breast cancer
2.1.1. Aberrant histone acetylation
Histone acetyltransferases (HATs) conventionally play an important role in the activation 
of gene expression by resulting in an open chromatin structure thus providing access for 
the transcription machinery to the DNA. There are different families of HATs identified thus 
far and their role in acetylating histones has been extensively studied. Histone acetylation is 
regulated by the activity of HATs as well as the histone deacetylases (HDACs), which remove 
the acetyl moieties from lysine residues. The acetylated lysines are read by reader proteins 
containing bromodomains (such as BRD2, BRD3 and BRD4) and depending on the complexes 
recruited by these “readers,” gene expression can be switched on or off [4].
In breast cancer, a study by Elsheikh et al. has identified low levels of the histone marks, 
H3K9Ac, H3K18Ac, H4K12Ac and H4K16Ac, to correlate with poorer prognosis and is asso-
ciated with basal and HER2-positive tumors. This study has also detailed the status of meth-
ylation on H3, which will be discussed in the following sections [18]. This altered epigenetic 
signature is hypothesized to be due to altered enzymatic activities of the HATs and HDACs, 
which could be attributed to their dysregulated expression. There are multiple lines of evi-
dence now to support this hypothesis. A ubiquitously expressed acetyltransferase p300/CBP, 
which is also known to function as transcriptional coactivator, was identified to be overex-
pressed in breast carcinoma as compared to adjacent normal mammary epithelia. Further, 
this study also showed that higher expression of p300 as studied by immunohistochemistry 
from a tissue microarray correlates with poorer prognosis-free survival and increased tumor 
recurrence [19]. However, it is unclear whether the role of p300 as a histone acetyltransferase 
or a lysine acetyltransferase (acetylating other non-histone proteins) is involved in this func-
tion and remains an interesting avenue for future studies.
Another acetyltransferase, TIP60, belonging to the MYST (MOZ, Ybf1, Sas2, TIP60) family of 
acetyltransferases is known to undergo mono-allelic losses in breast carcinomas as well as in 
head and neck tumors [20]. Low nuclear expression of TIP60 as evidenced by IHC correlates 
with higher tumor grade in breast cancer [20], suggestive of a tumor suppressive role played 
by this epigenetic regulator. One of the histone targets of TIP60 is the acetylation of Histone 
H4 at K16. A significant global reduction in histone H4 acetylation and lysine trimethylation 
has been observed across most cancer types including breast cancer [21]. This loss of mono-
acetylation was identified to be due to a reduction in the acetylation status of K16 and not the 
other putative mono-acetylated lysine on Histone H4 (K5, K8, K12 which are targets of p300/
CBP). Other acetyltransferases capable of acetylating K16 on H4 are MOZ (monocytic leuke-
mic zinc finger), MOF (male absent on the first) and MORF (MOZ-related factor). This study 
also identified the sequence specific loss of recruitment of MOZ, MOF, MORF in cancer cells 
as compared to the normal cells to the DNA repetitive elements associated with loss of H4K16 
acetylation (H4K16Ac) and H4K20 trimethylation (H4K20me3) [21]. In addition, independent 
studies have identified MOF mRNA and protein expression to be downregulated in breast 
carcinomas, and this was correlated with the reduced level of H4K16Ac acetylation in these 
tested primary breast carcinomas [22].
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The dysregulated histone acetylation in cancer can also be explained by changes in expres-
sion and function of histone deacetylases (HDACs). In breast cancer, HDAC1, HDAC2 and 
HDAC3 are identified to be differentially expressed as compared to the normal tissue and 
overexpression of HDAC2 and HDAC3 strongly correlates with a more aggressive tumor 
type, that is, negative hormone status [23]. This offers the opportunity of treating breast can-
cers with inhibitors of HDAC to restore acetylation level and suppress the tumorigenesis, and 
this approach will be detailed in the last part of this section which addresses the therapeutic 
implication of targeting the epigenetic regulators.
2.1.2. Aberrant histone methylation
Histones can be methylated (mono, di or tri) by enzymes that catalyze the transfer of methyl 
moiety to the lysine or arginine residues on the histone tails. The enzymes involved are known 
as histone methyltransferases (HMTs), while another class of enzymes, the histone demeth-
ylases (HDMs), is involved in erasing the methyl groups from the histone tails. The dynamic 
regulation between the HMTs and HDMs regulates the methylation status in the cells, thereby 
regulating cellular gene expression.
Studies have identified widespread changes in histone methylation in cancer cells as compared 
to the nontumorigenic counterparts. There is a global reduction in H4K20me3 in multiple 
cancer types including breast cancer [21]. Global reduction in H4K20me3 was also observed 
in human breast cancer cell lines compared to the nontumorigenic cells [24]. Further, in an 
established model of breast cancer in rats, there was a global decrease in H3K9 trimethylation 
(H3K9me3) and H4K20me3 indicating that these epigenetic dysregulations play an impor-
tant role in tumorigenesis [25]. In addition, another study has identified low levels of histone 
methyl marks, H3K4 dimethylation (H3K4me2), H4K20me3 and H4 Arginine dimethylation 
(H4R3me2) in human tumors, and these were found to correlate with poorer prognosis and 
more aggressive subtypes of breast cancer such as Luminal and HER2-positive tumors [18]. 
These global alterations in the level of methylation on histones are suggestive of an imbalance 
in the expression of methyltransferases as well as the demethylases.
In support of this notion, a variety of histone methyltransferases have been identified to be 
aberrantly expressed in breast tumors. Frequent overexpression and amplification of the his-
tone methyltransferase NSD3L have been observed in mammary carcinomas, and depletion 
of this enzyme decreased the invasiveness of breast cancer cells highlighting its potential as 
an oncogene. However, the targets of NSD3L-affecting tumorigenesis have not been eluci-
dated in detail [26, 27].
Enhancer of zeste 2 (EZH2) a methyltransferase that is a part of the Polycomb Repressive 
Complex 2 (PRC2) is found to be overexpressed in breast cancer, both at mRNA and protein 
level. The high expression of EZH2 is correlated with more aggressive cancer and a poor 
prognosis for patients. Overexpression of EZH2 in normal breast epithelia promotes anchor-
age independent growth, cell invasion, characteristics of a neoplastic phenotype in these cells, 
which is dependent on the suppressor of variegation 3-9 (Su(var)3-9), enhancer of zeste (E(z)), 
and trithorax (Trx) (SET) domain of EZH2 and HDAC activity [28]. This study paved the way 
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for many other groups to investigate the role of EZH2 enzymatic activity mediated by the SET 
domain, conventionally known to silence gene expression, in the context of breast carcinomas. 
H3K27 di and tri methylation are characteristic of Polycomb Group (PcG) target genes and 
are associated with transcriptional silencing. The PRC2 complex of which EZH2 is the cata-
lytic subunit with the other members being EED and Suz12 is involved in dimethylation and 
trimethylation of H3K27. The SET domain of EZH2 can function as an N methyltransferase, 
that is, EZH2 by utilizing S-adenosyl methionine (SAM) as a cofactor can add methyl groups 
to the lysine residues of substrate proteins. SET domain containing methyltransferases bind 
SAM and the substrate on opposite sides of the active site of the enzyme, thus SAM can dis-
sociate without interrupting substrate binding to enzyme, resulting in multiple methylations 
on the lysine residues [29, 30]. In breast cancer cell lines, increased EZH2 expression resulted 
in the down-regulation of a tumor suppressor, RUNX3. This was identified through chro-
matin immunoprecipitation to be due to the H3K27me3 at RUNX3 promoter and associated 
HDAC1, since depletion of EZH2 resulted in the loss of H3K27me3 and HDAC1 from this 
promoter and increased expression of RUNX3, which was associated with significantly lesser 
cell growth as compared to the siRNA control [31]. In addition, EZH2 also results in down-
regulation of another potential tumor suppressor, FOXC1, a transcription factor that has a 
role in differentiation and reduces cell migration and invasion. By trimethylating H3K27 at 
the FOXC1 promoter, EZH2 shuts down the expression of this transcription factor in a highly 
metastatic breast cancer cell line, MDA-MB-231 [32]. EZH2 is also known to repress RAD51, a 
protein involved in DNA repair and CDH1 (E-cadherin), a marker for epithelial cell type, loss 
of which results in increased invasiveness [33]. However, recent studies have also shown that 
increased EZH2 expression does not necessarily correlate with the H3K27me3 abundance. In 
particular, high expression of EZH2 was found in basal-like, HER2-positive and triple-nega-
tive tumors, while high H3K27me3 was found in normal-like (ER-negative), HER2-positive 
and Luminal A type tumors [34]. A possible explanation for this anomaly could be a non-
canonical catalytic activity independent function of EZH2. In triple-negative breast cancer 
(TNBC), it has been reported that EZH2 functions as an activator of NOTCH signaling. EZH2 
overexpression could increase NOTCH1 expression and accelerate mammary tumorigenesis 
in mice. It can bind to NOTCH1 promoter, a function that is independent of its ability to meth-
ylate histones [35]. This opens new doors to discover other functions of this epigenetic regula-
tor in mediating tumor progression by regulating nonhistone targets or affecting chromatin 
structure or in a manner independent of its catalytic function.
JARID1C, a histone demethylase, is also known to be upregulated and correlates with increased 
metastasis in breast cancer lesions compared to the normal counterparts. Mechanistically, 
JARID1C by modulating H3K4me3 at the promoter of breast cancer metastasis suppressor 
1 (BRMS1) represses the expression of BRMS1 and depletion of JARID1C results in reduced 
migration and invasion of breast cancer cells [36]. Enzymes belonging to the demethylase 
family of KDM4 are seen to be overexpressed in breast cancer and affect cell proliferation and 
growth of these cells [37]. KDM3A, a histone demethylase, which demethylates H3K9 mono 
and di-methyl moieties, works as a positive regulator of estrogen receptor (ER) activity. The 
catalytic activity of this enzyme is essential for ER target gene expression and growth of the 
cells, highlighting the significance of this methylation status in promoting tumorigenesis [38].
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2.1.3. Other histone modifications
Phosphorylation of histones is another posttranslational modification, which occurs on his-
tone tails and involves the kinase enzymatic activity. Serine, threonine and tyrosine residues 
on histone tails are known to be phosphorylated. H3S10 phosphorylation which marks the 
entry of the cell into mitosis is catalyzed by the enzyme Aurora B Kinase. Elevated expression 
of this kinase in several cancers is correlated with a poor prognosis for survival; however, it is 
not determined if this is due to the phosphorylation of H3S10 resulting in increased prolifera-
tive ability of cancer cells [39]. Ubiquitination is yet another posttranslational modification 
found on histones. Mono-ubiquitination of H2B (H2Bub1) is found to be globally reduced, 
and this is true in the context of breast cancer as well. Proteasome inhibition can reduce ERα-
mediated transcription, and this was due to reduction in H2Bub1 levels, which correlated 
with reduced transcription of ER target genes [40].
2.2. Chromatin remodelers in breast cancer
The chromatin compacts the DNA into the nucleus, and this regulates the accessibility of 
the wound DNA to transcription and repair machinery. One of the ways through which the 
chromatin is regulated has been discussed in the preceding section and involves extensive 
posttranslational modifications on histone tails. Apart from this, the locus-specific DNA 
methylation status can help in the recruitment of enzymes that alter chromatin structure, 
and this has also been discussed. Another way to regulate chromatin structure and function 
is by physically altering the nucleosome location or composition, and this process is known 
as chromatin remodeling. The groups of enzymes involved in restructuring the chromatin by 
this mechanism are referred to as chromatin remodelers and are further classified into dif-
ferent families depending on the associated cofactors. All chromatin remodelers utilize the 
energy of ATP hydrolysis to catalyze the reactions that affect histone-DNA interactions [41].
Remodelers are involved in mobilizing nucleosomes across the genome and regulate chro-
matin organization. They facilitate proper placement of nucleosomes whenever the DNA is 
accessed, for instance, before and after replication, repair and transcription. Remodelers also 
slide or evict nucleosomes and can replace them with a nucleosome that contains a histone 
variant. A common example is the histone variant H2AZ found flanking the transcription 
start site [41]. All these functions of remodelers suggest the important underlying role played 
by this group of epigenetic regulators in controlling basic cellular processes such as transcrip-
tion, chromatin assembly and DNA repair. Thus, it is not surprising that the altered expres-
sion or localization of these chromatin remodelers is correlated with tumorigenesis.
There are several families of chromatin remodelers such as SWI/SNF, INO80 and CHD com-
plexes, all of which are implicated in different cellular processes. Mutations in the SWI/SNF 
family of chromatin remodelers are found in about 20% of cancers, and some of these muta-
tions could have a gain-of-function phenotype while in the case of breast cancer as well as in 
leukemia, wild-type SWI/SNF complexes by their diverse protein interactions aid tumor pro-
gression [42]. The bipolar function of this important class of chromatin remodelers also impli-
cates the dynamic range of functions of remodelers and the myriad of their cellular interacting 
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partners, which assist their aberrant functions in cancer cells. In breast cancer, a member of the 
NuRD complex, a part of the CHD family of remodelers, is known to be aberrantly expressed. 
Metastasis-associated proteins (MTA-3) are associated with ER-positive breast cancer, and 
increased expression of these MTA-3 is correlated with increased ER expression as well as inva-
sive behavior. MTA-3 can directly repress SNAIL transcription in response to the ER stimulus; 
therefore, a decrease in either ER expression or MTA-3 expression results in increased metasta-
sis due to aberrant SNAIL expression [43].
ARID1A, a member of the human SWI/SNF complex, is known to undergo frequent muta-
tions across many cancer types. In breast cancer, ARID1A mRNA expression is seen to be 
downregulated in tumors as compared to adjacent normal tissues. This decreased expres-
sion was correlated with bigger tumor size and with the triple-negative breast cancers. 
Immunohistochemical staining also revealed a similar correlation between the protein level 
of ARID1A and tumor stage as well as the triple-negative tumor type [44].
Another member of the SWI/SNF complex, BAF155/SMARCC1 (BRG1-associated factor 155/ 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily C 
member 1) has been identified to play a critical role in breast cancer tumorigenesis in concert 
with a protein arginine methyltransferase coactivator-associated arginine methyltransferase 
1 (CARM1). CARM1 is highly expressed in many cancers such as breast and prostate with 
the levels of CARM1 higher in metastatic breast tumors as compared to the primary lesions. 
CARM1 is also implicated in the growth and proliferation of breast cancers by functioning 
as a coactivator of the steroid hormone receptors [45]. The arginine methylation of BAF155 at 
R1064 by CARM1 recruits BAF155 to a unique set of target genes such as genes in the c-MYC 
pathway. Intriguingly, there was a higher expression of both total and methylated BAF155 as 
observed by IHC in metastatic tumors, which were also associated with increased expression 
of CARM1 in these tumor samples. Patients with higher methylated BAF155 had a higher risk 
of tumor recurrence and poorer prognosis with a hazard ratio2 very similar to the aggressive 
triple-negative breast tumors [46]. This and other studies show the significance of chromatin 
reorganization and altered recruitment/function of chromatin remodelers to be an important 
hallmark of cancer cells and the need to target these reversible epigenetic changes for devel-
opment of more specific therapeutics.
Other examples of SWI/SNF family implicated in breast carcinogenesis are the Brahma and 
Brahma-related gene 1 (BRM and BRG1) that are overexpressed in breast tumors. Knockdown 
of either BRG1 or BRM reduced the proliferation of breast cancer cells, whereas a combined 
knockdown resulted in additive effect, suggesting independent pathways regulated by these 
chromatin remodelers in breast cancer progression [47].
A genetic mutation in BRCA1 predisposes women to ovarian cancer and significantly increases 
the risk for development of breast cancer. BRCA1 is predominantly found in cells in a com-
plex with members of the SWI/SNF family that is involved in chromatin remodeling. BRCA1 
2Hazard ratio: it is the ratio of the hazard rates of two groups being compared, that is, ratio of how often an event 
happens in one group compared to the other. In clinical trials, hazard ratios represent survival in a group of patients 
treated with a drug at any point of time with the other group given a placebo/different treatment. A hazard ratio of 1 
indicates no difference in survival while a ratio greater or lesser than 1 indicates one of the groups has a better survival.
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directly interacts with BRG1, and this interaction is essential for BRCA1 transcriptional coacti-
vation function. A dominant negative mutation of BRG1 or the deletion of exon 11 of BRCA1 
(implicated in cancer) results in abrogation of p53 stimulated BRCA1 transcriptional activ-
ity. This underscores the importance of chromatin organization and remodeling by BRG1 
and BRCA1 to control BRCA1 transcriptional activity, loss of which results in increased risk 
for tumor development [48]. Additionally, interaction of mutant p53 with the SWI/SNF com-
plex leads to open chromatin structure at the Vascular Endothelial Growth Factor Receptor 2 
(VEGFR2) promoter in breast cancers that leads to the upregulation of VEGF2. This aids the 
growth of cancer cells in two and three dimensional cultures. Thus, mutant p53 by regulating 
a major family of chromatin remodelers promotes tumor progression [49].
2.3. Aberrant DNA methylation in breast cancer
DNA methylation is another form of epigenetic regulation that involves the addition of 
a methyl moiety to the 5′ cytosine of a CG dinucleotide, which are distributed across our 
genome and are enriched at the gene promoters to form the Cytosine preceding Guanine 
(CpG) islands. DNA methylation is conventionally associated with gene silencing due to 
the steric blocking of transcription factors by the methyl moieties, thereby preventing gene 
expression. In addition, methyl binding proteins such as MeCP2, MBD2 and MBD3 which can 
physically interact with both DNA methyltransferases as well as histone methyltransferases 
(Suv39h1 which adds H3K9me3), HDACs and Heterochromatin protein 1 (HP1), recruit this 
repressive complex to synergistically shut off gene expression of genes with methylated pro-
moters [50, 51]. The enzymes involved in DNA methylation are the de novo methyltransferases 
DNMT3a and DNMT3b which establish new silencing patterns in response to environmental 
cues and the maintenance methyltransferase DNMT1 which is responsible for maintaining 
the heritable silencing patterns [50].
Abnormal changes in DNA methylation patterns are widespread across all cancer types 
including the breast cancer genome. Paradoxically in cancer, there are two distinct aber-
rations—a global hypomethylation observed as a result of an increased expression of 
demethylases and gene-specific hypermethylation events possibly due to the inaccessi-
bility of the demethylases to the chromatin structure, both of which could contribute to 
tumorigenesis [52, 53].
In breast cancer too, a specific cohort of genes is known to be hypermethylated, and therefore, 
their expression is turned off. This happens at promoters of potential tumor suppressor genes 
involved in regulation of cellular proliferation, invasion, and metastasis. A few examples of 
such genes are CDH1 (E-cadherin), BRCA1, 14-3-3σ, ERα, ERβ, RARβ and TIMP3 [54].
The importance of methylation in regulating gene expression in a cell- and tissue-specific 
manner becomes evident on analysis of breast tumor samples for DNA methylation. Different 
studies by performing methylation specific PCRs have described the concept of methylation 
index,3 which is a ratio of genes hypermethylated to the total number of genes studied. It is 
3Methylation index (MI): It is a reflection of the fraction of genes methylated. It is a ratio of the total number of genes 
methylated to the total number of genes analyzed. MI can be used to predict the risk of cancer.
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observed that a higher methylation index correlates with a poorer prognosis and increased 
risk of recurrence of breast cancer [55]. Of more clinical significance is the finding that pro-
moter hypermethylation events can be detected from patient serum samples. In a study by 
Wong et al., the authors, from peripheral blood samples determined that BRCA1 promoter 
methylation increases the risk for development of breast cancer by 3.5 fold [56]. Another 
study has identified genome-wide differential methylation of CpGs in breast tumors com-
pared to normal breast tissues. Interestingly, this study has also identified the differences in 
methylation between different molecular sub types of breast tumors, highlighting that the 
altered epigenetic circuitry could result in a different outcome for the disease. While Luminal 
B, Luminal A and HER2-positive tumors were extensively methylated in the CpGs, the basal-
like tumors showed a distinct methylation pattern compared to the other sub types. The DNA 
methylation in Luminal A and HER2 tumors was more heterogeneous reiterating that breast 
cancer as a disease is constantly evolving and dynamic. They identified a distinct signature 
of DNA methylation in Luminal B tumors which are principally associated with CpG meth-
ylation at promoters, while, in contrast, basal-like tumors are marked by hypomethylation 
events in the gene body. This has led to classifying tumors from Luminal A, HER2 subtypes 
which exhibit signatures of CpG methylation similar to either Luminal B or basal-like as Epi-
LumB or Epi-Basal respectively, highlighting the importance of these epigenetic changes in 
underlying tumor progression. Both Epi-LumB and Epi-Basal types of tumors were signifi-
cantly correlated with increased tumor size, and Epi-LumB type tumors were found to be 
associated with shorter patient survival times [57]. This indicates the potential for the use of 
DNA methylation events in a clinical context for diagnosis and personalized treatment as well 
as targeting these methylation marks for discovery of therapeutics.
As discussed earlier, hypomethylation events in cancer are also associated with a poorer 
prognosis. The demethylation of tumor supportive genes that aid proliferation and metas-
tasis such matrix metalloproteases-9 (MMP9) and urokinase plasminogen activator can in 
part explain this paradox about both hypomethylation and hypermethylation events in breast 
cancer increasing tumorigenic potential. Treatment of nonmetastatic breast cancer cells with 
demethylating agents increases their metastatic potential, while, in contrast, treatment with 
agents that reverse demethylation decreases the invasive capacity of breast cancer cells [58–60].
Apart from 5-methylcytosine, other methylation modifications on DNA include 5-hydroxy-
methylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), all of which 
are regulated by Ten-Eleven Translocation (TET) proteins. TET proteins, in an α-Ketoglutarate 
and Fe(II)-dependent manner, catalyze the oxidation of the methyl groups on DNA, and these 
modifications could also function as intermediates in the demethylation of DNA [61, 62]. 
There are three known TET members identified in mammals, which include TET1, TET2 and 
TET3. They vary in structure and thus catalyze the oxidation reactions with varying efficien-
cies [63]. Inactivating mutations in TET2 have been identified in about 15% of myeloid tumors 
and in patients with myelodysplastic syndromes [64, 65]. Studies by different groups have 
identified a significant reduction in 5hmC levels in solid tumors including breast, colon, lung, 
pancreatic, prostate, colon and gastric tumors [66, 67]. Interestingly, these reductions in 5hmC 
levels were accompanied by a significant decrease in expression of TET1, TET2 and TET3 in 
liver and breast carcinomas compared to the adjacent normal epithelia [66].
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In the context of breast cancer, 5hmC levels are known to be deregulated. An example is the 
lower level of 5hmC mark at the promoter of a prominent tumor suppressor, Leucine zipper, 
putative tumor suppressor 1 (LZTS1) in breast cancer patient samples compared to normal 
breast tissues from healthy individuals. This results in a lower expression of LZTS1, and this 
lower expression as well as reduced TET1 expression was correlated with 5hmC levels in the 
tumors. Further, lower levels of 5hmC were also associated with unfavorable prognosis and 
lymph node involvement [68]. High mobility group AT-hook2 (HMGA2), a chromatin remod-
eler, which is known to be overexpressed, regulates the expression of TET in breast cancers. 
Knockdown of HMGA2 in both cell lines and mouse breast tumors induces the expression of 
TET1. TET1 in turn demethylates its own promoter as well as Homeobox A (HOXA) genes 
such as HOXA7 and HOXA9. This induces the expression of TET1 as well as the HOXA genes 
which together suppress the breast cancer growth and metastasis in mouse xenograft models 
[69]. This study also uncovers the potential of using the novel HMGA2/TET1/HOXA9 axis as 
a prognostic tool for breast cancer patient survival [69]. Further, under hypoxic conditions, 
which are a characteristic of many solid tumors including breast tumors, studies have shown 
an increase in expression of TET1 and TET3. The expression of TET1 and TET3 correlated 
with tumor hypoxia in patient samples and poorer prognosis and survival. Under hypoxic 
conditions, TET1 and TET3 proteins demethylate promoter of TNF-α and thus activate the 
TNF-α-p38-MAPK signaling pathway and thereby contribute to tumor progression in vitro 
and in vivo [70].
The complexity of epigenetic regulation by DNA methylation is evident from these numer-
ous studies. All the studies indicate the possibility of using DNA methylation as well as DNA 
hydroxymethylation as predictive biomarker for breast cancer especially for early detection of 
these tumors. Evidence for this is provided by numerous studies which highlight that methyl-
ation signatures are more correlated with clinical patterns as compared to the gene expression 
and suggest a combination of these to expand the current classification and clinical prog-
nosis predictions. Specifically, methylation pattern of promoters of RASSF1A, MAL, SFRP1, 
BCAP31, and BRCA1 can be used in combination with other gene promoters to increase speci-
ficity and statistical power to predict clinical outcome [71, 72].
2.4. Targeting epigenetic regulators in breast cancer
Breast cancer, especially the triple negative subtype, is highly aggressive and needs an 
exhaustive list of treatment options to be made available for the patients. Understanding the 
dysregulated epigenetic circuitry has now made it possible to search for cures targeting the 
reversible marks put by the epigenetic regulators. Furthermore, methylation and acetylation 
marks as discussed earlier have shown immense potential to serve as candidate biomarkers, 
highlighting the need to monitor their levels for early diagnosis and treatment. The use of 
these biomarkers and screening of patients for potential biomarkers also facilitates in improv-
ing the individualized therapy and personal medicine, moving away from the conventional 
“one size fits all” to cater to the needs of the individual patients.
Current treatment strategies for breast cancer include surgery for removal of local tumors, 
adjuvant therapy in the form of chemotherapy, hormone therapy and targeted therapy. 
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Treatment of basal-like breast tumors involves treatment with EGFR inhibitors and PARP 
inhibitors [73]. However, they all suffer from drawbacks mainly due to unprecedented side 
effects of these drugs. The two most studied therapeutic agents, which regulate epigenetic fac-
tors, are DNA methylation inhibitors and histone deacetylase inhibitors and will be detailed 
in this section. The major challenge for “epi-drugs” is to recapitulate the efficient action from 
cell-based studies in the clinical context.
The two most used DNA methylation inhibitors are 5′ Azacytidine (5-Aza) and 5-aza-2-de-
oxycytidine (decitabine). Treatment of ER-negative breast cancer cells with 5-Aza reactivates 
the expression of ER at both mRNA and protein level. In addition, preclinical evidence sug-
gests a useful role for DNMT inhibitors (DNMTi) in breast cancer treatment. Nanomolar (nM) 
dose of DNMTi has resulted in reactivation of silenced tumor suppressors such as ER, BRCA1 
and PTEN in breast cancer cell lines [74]. However, there are no available clinical data for 
the efficacy of these drugs in breast cancer. These drugs though having improved survival of 
patients with myelodysplastic syndrome and low blast count AML (lower number of imma-
ture blood cells called myeloblasts or blasts for short which are not normally found in the 
blood) have disappointingly not shown much promise in solid tumors. Other nucleoside ana-
logs like zebularine and antisense oligo to specifically inhibit DNMT1 (MG98) are in clinical 
development. There have been clinical studies that used a combination of HDAC inhibitors 
(HDACi) and DNA demethylating agents and have shown promise. A phase I study used a 
combination of decitabine and vorinostat (HDACi) in cancer patients with advanced disease 
and showed stabilization of the disease in seven of the 22 evaluable patients of which 2 were 
patients with breast cancer [75].
HDAC inhibitors function by inhibiting the activity of the enzymes responsible for catalyz-
ing the removal of acetyl moieties from proteins, the HDACs. HDACs are divided into four 
classes, and current HDACi therapy focuses on inhibitors for Class I and Class II HDACs that 
include HDACs 1–10. The only HDAC inhibitor that has FDA approval is Vorinostat. HDAC 
inhibitors result in increased acetylation of histones which is associated with reactivation of 
tumor suppressor genes such as p21 and p27 which in turn have the potential to inhibit tumor 
cell growth [76]. Vorinostat can inhibit the proliferation of breast cancer cells irrespective of 
their ER status. Treatment of vorinostat concomitantly with another HDACi, LAQ824, sensi-
tizes ER positive cells to tamoxifen therapy by downregulating expression of phosphorylated 
and total Akt (also known as Protein Kinase B [PKB] and originally identified as an oncogene 
from the AKT-8 retrovirus). HDAC inhibitors such as Vorinostat used in combination can 
enhance the effect of tamoxifen in the hormonal strategies to treat breast cancer, whereas 
the mechanistic studies are still exploring the pathways involved in reversal of resistance to 
hormonal therapy. There are several ongoing phase II trials of combination of HDACs such as 
vorinostat, entinostat and valproic acid (VA) with tamoxifen, chemotherapeutic agents such 
as epirubicin and paclitaxel, which show promising results in treatment of the metastatic 
disease [75].
In a notable exception to the use of HDAC inhibitors, a study found that HDAC inhibitor 
valproic acid (VA) stimulates the self-renewal and expansion of normal hematopoietic stem 
cells [77]. In addition to this, VA enables cells to be reprogrammed to induced pluripotent 
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stem cells [81, 82]. VA was found to have a differential effect on breast cancer cells that were 
differentiated in vitro compared to breast cancer cells that had stem cell–like characteristic, 
in that it radiosensitized the already differentiated cells as compared to radioprotecting the 
cells that had stem cell–like characteristic [83, 84]. An HDAC inhibitor as such, therefore, 
can lead to cancer stem cells being formed by dedifferentiating the cells that have non–stem 
cell–like characteristic to the ones that have the phenotype of stem cells. Chen H. et al. treated 
the patient-derived breast cancer cells and highly metastatic cell lines with HDAC inhibi-
tors and found that the capacity to initiate tumor formation was high in cell lines that had 
non–stem cell–like characteristic, and the signaling pathway found to be involved was the 
WNT/β-catenin [83]. Therefore, in summary, it is extremely important that clinical studies 
using HDAC inhibitors should be done with extreme caution, and all possible effects should 
be taken into consideration before combinatorial use in trials.
Intriguingly, these epigenetic regulators and the key aberrantly regulated pathways in breast 
cancer including ERα signaling share a complex dynamic, which influences the treatment 
regime and also directs resistance to certain therapeutics. This interplay between epigenetic 
control and signaling from cell surface receptors has been detailed in the following section.
3. Epigenetic control of signaling pathways in breast cancer
A cell’s response to external stimuli requires the activation of a signaling cascade. These signal-
ing cascades can be either linear or multinodal where different signal transduction pathways 
converge resulting in the translocation and integration of these signals into the activation or 
repression of gene expression [78]. Signaling pathways crosstalk among each other to regu-
late the gene expression patterns by modulating downstream effectors such as transcription 
factors, cofactors and histone modifiers. This coordinated activation of signaling pathways 
impacts the epigenetic landscape and plays a major role in translating a signaling event into 
a long-lasting molecular and phenotypic change. Analyzing the relationship between cell sig-
naling and epigenetics is of utmost importance, as it will help us extend our vision on how a 
cell is able to integrate information from external and/or internal stimuli to gene expression 
regulation through chromatin modifications.
The combined action of a cell-type–specific transcription factor and signal effectors on regu-
latory elements of the genome is strongly influenced by the chromatin landscape of a given 
cell, resulting in the establishment of a dynamic interplay between signaling pathways and 
the epigenetic machinery leading to the development of different cancer types including 
breast cancer. Globally, most of the frequently mutated somatic genes are ER, HER2, AKT and 
MAPK, and these are regulated by epigenetic modifications suggesting the interplay of these 
regulatory networks in breast cancer tumorigenesis [79].
In this section, we will discuss the interplay between signaling pathways and epigenetic reg-
ulators with special emphasis on estrogen receptor signaling. We will highlight how chro-
matin modifications triggered by extrinsic signaling in breast cancer play a critical role in 
 pathological events leading to tumorigenesis.
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3.1. Epigenetics of estrogen receptor signaling
Epigenetic changes can be defined as stable molecular alterations of a cellular phenotype that 
are heritable during somatic cell divisions but do not involve changes in the DNA sequence. 
Epigenetic regulation is critical in normal growth and development and closely coordinates 
the transcriptional expression of genes. Estrogen refers to a family of hormones responsible 
for the development and regulation of the female reproductive system and secondary sexual 
characteristics. Estrogen is produced by the ovaries and in smaller amounts by the adrenal 
cortex, testes, and fetoplacental unit [80]. Although estrogen is considered to be a female hor-
mone, it is present in both sexes. Estrogen is found in three naturally occurring forms, such 
as estrone (E1), estradiol (E2) and estriol (E3). Another type of estrogen called estetrol (E4) is 
produced only during pregnancy. The steroid 17β-estradiol is the most potent and prevalent 
estrogen among the group. Estrogen is known to play an important role in a variety of bio-
logical processes. It is involved in growth, differentiation, development of brain and has an 
important role in reproduction [87]. Estrogen plays an important role in controlling hormonal 
effect; therefore, high levels of estrogen increase the risk of the development of breast cancer 
as high levels increase the transcription of genes known to be involved in the cell cycle regula-
tion and metabolism pathways [88, 89].
Estrogen diffuses across the cell membrane where it binds and activates its receptor, the estro-
gen receptor (ER) that plays an important role in the action of estrogen. The biological effects 
of estrogen are mediated by its binding to the structurally and functionally distinct estrogen 
receptors (ERα and ERβ) [81]. ERα is a member of the steroid/thyroid hormone and vitamin 
A/D nuclear receptor super family [82]. ERα plays a role in regulation of genes in a diverse 
set of target cells that are involved in the estrogen-activated pathway and is therefore also 
referred to as a nuclear receptor that is activated by ligand. In addition to playing a role in 
normal development, ERα and its ligand 17β-estradiol have been known to be involved and 
are implicated in the progression of breast cancer [91]. The function of ERβ has been detailed 
recently; however, studies to determine its role in breast cancer development and/or progno-
sis are still ongoing. The role of ERβ in breast cancer remains elusive, but the presence of ERα 
at the time of diagnosis is used as an indication for endocrine therapy. Pathological estrogens 
have been associated with a higher risk of breast cancer as estrogen stimulation induces modi-
fications of histones at the promoter region of ERα gene such as phosphorylation, methylation 
and acetylation by interacting with various enzymes of the epigenetic pathway that induces 
these histone modifications [88, 92]. These enzymes if deregulated lead to neoplastic transfor-
mation driven by ERα [88].
3.1.1. Mechanism of ERα-mediated histone modifications
The transcriptional outcome of ERα is regulated by a dynamic interaction of histone-mod-
ifying enzymes and associated coregulators. The multiprotein complexes containing ERα, 
its coactivators such as p300/CREB-binding protein (p300/CBP), p300/CBP-associated factor 
(PCAF) [83] and histone-modifying enzymes such as acetylases/deacetylases and methylases/
demethylases assemble in response to hormone binding, resulting in transcriptional regulation 
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[84]. ERα exerts a positive feedback loop on expression of CYP19A, which is involved in the 
synthesis of estrogens in human placenta, thereby promoting induction of its own gene at the 
transcription level and contributing to local estrogen synthesis by promoting increased acety-
lation in the CYP19A promoter [85]. ERα also enhances the recruitment of metastasis-associ-
ated 1 protein (MTA1), a component of the histone deacetylase and nucleosome remodeling 
complex (NuRD), in a ligand and growth factor signaling dependent manner, resulting in the 
attenuation of ERα signaling [86]. MTA1 interacts with histone deacetylases directly and hence 
behaves as a corepressor. Dysregulation of MTA1 leads to cell migration, formation of colonies 
in semisolid media [97], mammary carcinoma development in transgenic mice [98] and breast 
cancer cells growth in some experimental observations. In addition, inhibiting the expression 
of MTA1 protein also led to growth inhibition and reduced invasion of highly metastatic breast 
cancer cells MDA-MB-231, making it an important molecule in breast tumorigenesis [99].
ERα signaling pathway has traditionally been known to be involved in the activation of genes 
involved in transcription; however, recent observations using experimental techniques such 
as microarray and ChIP have found that in transcriptome of more than half of ERα target 
genes regulated by ERα are repressed [100]. Different chromatin modifications at the ERα 
target genes as well as recruitment of different regulators of transcription may account for 
differential regulation by ERα. One of the examples of this regulation is the repressor of estro-
gen receptor activity (REA) and its binding partner EZH2. EZH2 is an important corepressor 
that is upregulated during the progression of different cancers, a process accompanied by 
the silencing of various genes. Interestingly, EZH2-mediated repression of cellular genes was 
attenuated on inhibition of histone deacetylase activity, implying a dependence of EZH2 tar-
gets on acetylation status of histones as well as chromatin remodeling [87]. In another study 
by Jene-Sanz et al., it was found that EZH2 targets tumor suppressor genes, because EZH2 
overexpression not only repressed a significant number of genes but also resulted in increased 
metastasis [88]. Therefore, the combined interaction of EZH2 with the repressor of estrogen 
receptor is needed for ERα’s recruitment to specific target genes and repression of estrogen-
dependent transcription [89]. The inhibition of EZH2 by siRNA was found to be responsible 
for an increase in estrogen-dependent transcription.
ERα also modifies chromatin organization by affecting the acetylation and deacetylation of 
conserved lysine residues present in histone tails. Specifically, the coactivators of ERα possess 
histone acetyl transferase activity and are known to associate with and modulate functions 
of specific acetyl transferases. In addition, ERα-mediated deacetylation is accomplished by 
recruitment of histone deacetylases (HDACs), which are recruited indirectly to ERα target 
genes through multisubunit corepressor complexes. ERα also utilizes corepressor complexes 
such as nuclear receptor corepressor (NCOR) and silencing mediator of retinoid and thyroid 
hormone receptors (SMRT) that associate with histone deacetylases [90]. Studies employ-
ing siRNA targeting histone deacetylases and corepressors indicated that one such histone 
deacetylase, HDAC6 functions with a corepressor, ligand-dependent corepressor (LCOR) 
on some ERα target genes as part of a feedback loop to regulate estrogen-dependent gene 
regulation in breast cancer cells [91]. The expression levels of HDAC6 correlate with better 
prognosis and response to endocrine therapy in breast cancer patients. Thus, ERα is known 
to achieve several histone modifications at target gene promoters using several coregulators.
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Studies on ERα target gene regulation have introduced a new degree of complexity, wherein a 
combination of interactions between ERα and histone acetyltransferases, histone deacetylases, 
histone methyltransferases, coactivators, corepressors and transcription factors reveals a complex 
histone code that regulates promoters involved in breast cancer cells proliferation. A dynamic 
process of DNA methylation is also known to be involved in the control of the cyclic expression of 
ERα target genes. In a significant fraction of breast cancers, the absence or loss of ER at the time of 
diagnosis or treatment is due to aberrant methylation of CpG islands, cytosine-guanine-rich areas 
that are located in the 5′ regulatory regions of the ERα gene [92, 93]. Methylation/demethylation of 
CpG sites on promoters following estrogen stimulation revealed the importance of DNA methyl-
transferases control on estrogen-dependent gene expression. Interestingly, ERβ has been found 
to play a role in the establishment of new and stable methylation. All these results provide strong 
evidence that estrogen target gene expression is tightly regulated by multiple highly dynamic 
machinery affecting estrogen receptor in both a transcriptional and an epigenetic manner.
Current endocrine therapy for ERα-positive cancer involves modulating the ERα pathway 
using antiestrogens (AEs) or aromatase inhibitors (AIs). ERα’s ability to modulate epigen-
etic changes by regulating writers, erasers and readers of epigenetic modifications provides 
a unique therapeutic opportunity to design novel drugs and small molecular inhibitors for 
treating ERα-positive cancers [88] (Figure 3).
Figure 3. Regulation of epigenetic modifications by ERα. Estrogen signaling activates a set of kinases via its extra-
nuclear signaling that modifies histone tails or influences the recruitment and function of histone modifying enzymes. 
In addition, ERα-driven transcription also involves a coordinated interaction of ERα with acetylases/deacetylases and 
methylases/demethylases. ERα if deregulated affects tumor progression and its associated therapeutic resistance.
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3.2. Linking chromatin to the downstream signaling effectors
Eukaryotes utilize the chromatin landscape as its epigenetic template within the nucleus of 
living cells to promote gene transcription in response to environmental signals. Different 
classes of chromatin-associated enzymes or kinases that play important role in modulating 
chromatin structure within the human genome have been discovered recently. These signal 
transduction kinases play a pivotal role as chromatin-anchored proteins in eukaryotes, relay-
ing signals from the cytoplasm to the nucleus and direct the association of chromatin-bound 
transcription complexes at activated targets in the nucleus [94]. These interactions serve to 
integrate the hormonal signals into a network of coordinated programs, and it is the outcome 
of this integration that specifies the nature, intensity and duration of the cellular response.
Estrogen and progesterone, two of the hormones known to play a role in breast cancer progres-
sion influence a variety of functions via their respective signaling cascades. These steroid hor-
mone receptors (SHR) are known to interact with hormone-responsive elements (HREs) in the 
promoter/enhancer region of target genes, thereby affecting the epigenetic landscape of the cell 
[95]. SHRs can also activate genes lacking HREs by interacting with other sequence-specific tran-
scription factors bound to their target sequences [96]. In addition to nongenomic interactions that 
involve the activation of PI3K/Akt pathways by the interaction of the ERα with the regulatory 
subunit of PI3K, SHRs can also induce direct genomic affects by binding to different regulatory 
elements of the genome and inducing the downstream effector response. Not much has been 
reported or is known on how progesterone receptor integrates the signaling pathways at the epi-
genetic level. A study by Ballare et al.using a synthetic progesterone, progestin, found that some 
of the kinases activated by progestin in the cytoplasm phosphorylate the progesterone receptor 
(PR) and form a complex with the activated receptor. This complex is recruited to the target sites 
where the kinases modify the protruding core histone tails and the linker histones. These modi-
fications lead to the displacement of linker histones and a repressive complex, by recruiting spe-
cialized ATP-dependent remodelers such as switch/sucrose nonfermentable (SWI/SNF) [97]. In 
addition, other specialized ATP-dependent remodelers displace histone H2A/H2B dimers from 
the promoter nucleosome, enabling synergistic access of other transcription factors and additional 
receptor complexes to previously hidden binding sites on the surface of a histone H3/H4 tetramer 
particle [95]. It is only after completion of these initial chromatin remodeling steps that complexes 
containing mediator and RNA polymerase along with associated basal transcription factors are 
recruited, and further steps in transcription can take place. Thus, these signaling pathways of 
progestin action converge on the chromatin to enable gene regulation in the case of breast cancer.
3.2.1. Role of kinases in the epigenetic signaling network
Cross talk between signaling kinases and chromatin remodelers are critical for eliciting induc-
ible transcriptional programs that include differentiation of cells, their ability to invade and 
migrate and to form cancer stem cells. Epigenetic approach targeting breast cancer stem cells 
(CSCs) may prove to be a good therapeutic option since not much has been known about 
the cross talk between these signaling kinases and chromatin remodelers. In an exception, 
one study found the chromatin-associated role of an evolutionarily conserved protein kinase 
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C (PKC) family protein, PKC-θ. After nuclear translocation to the nucleus, PKC-θ plays a 
role in generating a T cell–induced immune response by influencing the transcription of 
genes involved in generating the response that also include some microRNAs [112]. Aberrant 
expression of this kinase may lead to uncontrolled cell growth leading to tumors, inflamma-
tory disorders or an aggressive form of breast cancer leading to cancer metastasis [113].
PKC-θ is present mainly in ER-negative basal-like breast cancer lines, localized in the 
nucleus, and an increased nuclear PKC-θ results in epithelial to mesenchymal transition 
(EMT). Experiments such as ChIP using pan-PKC-θ-specific antibody was performed, and it 
was found that PKC-θ occupies the proximal promoter region of CD44 gene in EMT models. 
Additionally, ChIP analysis demonstrated that RNA polymerase II and PKC-θ coexist on 
the promoter of CSC-inducible gene suggesting that PKC-θ exists as part of a transcription 
complex in the mesenchymal state [98]. Thus, active PKC in primary breast cancers teth-
ers the transcription complex to EMT and CSC-inducible genes, and the expression of this 
complex is found elevated in cancer stem cells leading to breast cancer. The PKC pathway 
also cooperates with the transforming growth factor β (TGF-β) pathway and collaborates 
with the NF-κB pathway to promote a distinct transcriptional program of inducible EMT 
and CSC signature genes [99]. Using the p50 and p65 heterodimer (the subunits of NF-κB 
pathway), the transcription complex of activated PKC-θ is bound to the chromatin of some 
inducible genes that are involved in the EMT process. The role of each of the subunit is 
such that p65 subunit recruits the PKC-θ transcriptional complex to the promoter region of 
CD44 and IL-6 and the p50 subunit is involved in the recruitment of PKC-θ transcriptional 
complex to only the promoter region of IL-6 but not to CD44. In a cellular system if PKC-θ 
is knocked out, it is observed that PKC-θ is not only important for maintaining a permis-
sive state for IL-6 and CD44 at the chromatin level but also for the enrichment of certain 
epigenetic marks such as H3K4me3 and H3K9ac [113]. Using genome-wide analysis, dis-
tinct cohorts of inducible PKC-θ sensitive genes in the mesenchymal state that are directly 
tethered to chromatinized PKC-θ were identified. Some of the genes were found to be EMT 
regulators and some involved in progression of cancer, suggesting that PKC-θ occupies a 
position upstream making it a novel regulator of the EMT process and in the progression of 
cancer. Thus, the chromatin bound PKC-θ engages with factors that play a role in establish-
ing a permissive chromatin state, thereby contributing a new dimension toward the under-
standing of EMT/CSC process in breast cancer. Targeting CSCs remains an underdeveloped 
area of cancer therapy; however, a novel epigenetic mechanism using specific inhibitors will 
pave the way for novel “epitherapeutic” strategies.
Some other examples of signaling pathways influencing the epigenetic circuitry include the 
NF-κB pathway. Tumor necrosis factor α (TNF-α), an important effector of the NF-κB path-
way, is known to induce expression of a lysine demethylase, KDM4D in macrophages and 
dendritic cells. Enzymes belonging to the demethylase family of KDM4 including KDM4D 
are overexpressed in breast cancer and affect cell proliferation and growth of these cells [98]. 
Another lysine demethylase of KDM4 family, KDM4A, has been known to be involved in 
transcriptional regulation, where it may either stimulate or repress gene transcription [100]. 
The latter function involves the association with nuclear receptor corepressor complex or 
association with histone deacetylases. KDM4A is also known to form complexes with ER 
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and to stimulate its activity. Accordingly, depletion of KDM4A in ER-positive breast cancer 
cells leads to a decrease in the expression of ER targets such as the c-JUN and Cyclin D1 
oncogenes and reduced cell growth [101]. Similarly, KDM4A knockdown inhibited prolifera-
tion of ER-negative MDA-MB-231 and ER-positive MCF7 breast cancer cells [102, 103], sug-
gesting that KDM4A is critical for growth of both ER positive and negative breast cancers. 
Another example is the progesterone-activated extracellular signal-regulated protein kinase 
1/2 (ERK1/2) pathway in breast cancer, which phosphorylates both the progesterone receptor 
and the downstream kinase, mitogen and stress-activated protein kinase 1(MSK1), forming 
an active ternary complex that mediates the phosphorylation of histone H3 at serine 10 in 
breast cancer cells [104]. This initial step triggers the recruitment of histone modifiers and 
chromatin remodeling complexes, which ultimately leads to displacement of histones H1 and 
H2A/H2B supporting the role of chromatin remodeling complexes for transcriptional activa-
tion of progesterone responsive genes.
In the case of ERα signaling, ER activates a number of kinases in the extranuclear com-
partment including protein kinase B (AKT) and extracellular signal-regulated protein 
kinase. In ER-positive breast cancers, mitogen-activated protein kinase (MAPK) pathway 
exerts an effect at the level of ER-induced transcription as well as at the level of the cell 
cycle regulation. Estrogen stimulates cell proliferation by activation of MAP kinase, either 
through rapid, nontranscription effects or by increasing growth factor production and con-
sequently MAP kinase expression. Hormonal stimulation also promotes alterations in the 
phosphorylation of specific residues in histone tails via modulation of these extra-nuclear 
kinases. Estrogen-ERα signaling activates MAP kinase cascades in breast cancer specifi-
cally the one involving ERK-1 and ERK-2 that transmit and amplify signals involved in 
cellular proliferation [105]. ERα activates ERK2, resulting in its chromatin binding and 
enabling ERK2 modulation of estrogen-dependent gene expression and proliferation in 
breast cancers. This convergence of ERK2 and ERα at the chromatin level is also known to 
activate an oncogenic kinase AuroraA/B to directly affect nuclear receptor activities [106]. 
The Src-AKTs, which are involved in phosphorylation of Histone H1 and Src-MAPK path-
ways, are also activated by ERα signaling. Downstream substrates of these kinases such as 
the ones that phosphorylate histone H1 and core histones are therefore influenced by ERα 
signaling at the chromatin level [122]. In addition, the expression of several phosphates 
such as PP1 and PP2A is also regulated by the ERα signaling. In one of the studies, these 
phosphates were identified as key negative regulators of steroid receptor coactivator 3 
(SRC-3). SRC-3 is a coactivator and an oncogene, whose phosphorylation transforms it 
into a powerful coregulator. It was shown that PDXP and PP2A dephosphorylate SRC-3 
and inhibit its ligand-dependent association with estrogen receptor, thus regulating the 
oncogenic cell proliferation and invasion functions of SRC-3 in breast cancer cells [107]. 
These observations therefore suggest that ERα-extranuclear signaling has the potential to 
modulate epigenetic modifications. The direct communication between the extracellular 
environment and the regulation of gene function may be even more widespread and war-
rants greater study. It could involve many kinases that are known to regulate gene expres-
sion indirectly via signaling cascades. In addition, the signaling to chromatin may change 
the role of these kinases and may rationalize the use of chromatin-modifying enzymes as 
important cellular targets.
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3.3. HDACs and signaling pathways
Sustained and increased hormone and growth factor receptor signaling in breast cancer cells 
contributes to resistance toward endocrine therapy. It has become important to modulate 
the signaling pathways so as to design an attractive strategy in overcoming potential resis-
tance to endocrine therapy. In the case of breast cancer, down regulation of ERα expression 
is one of the mechanisms behind the acquisition of endocrine resistance. Histone deacety-
lases (HDACs) are important epigenetic regulators and are overexpressed in multiple can-
cers, including breast cancer. Specifically, histone deacetylase 1 (HDAC1) is an important 
epigenetic regulator involved in transcriptional regulation through modification of chromatin 
organization [82]. Although, HDACs are primarily known to repress gene expression as part 
of corepressor complexes, recent findings by Smith et al. have established a link between 
HDACs inhibition and repression of gene expression, suggesting that they might also func-
tion as coactivators [108]. In some cases, as for the regulation of ERα, HDACs inhibitors 
(HDACi) can have both positive and negative impact on transcription, depending on the cell 
context. In breast cancer cells, trichostatin A (TSA), a potent and reversible HDACi, produced 
a strong decrease in ERα accumulation independent of the presence or absence of ER ligands. 
The effect was dose dependent and was not restricted to TSA since a similar regulation was 
obtained with different HDACi, suberoylanilide hydroxamic acid (SAHA), which is struc-
turally similar to TSA [109]. Regulation by TSA takes place at the transcriptional level and 
therefore the use of different HDACi decreases the expression of ERα in ER-positive breast 
cancer cells. In another study, it was found that the use of HDACi reactivates the expression 
of the receptor in ER-negative cells and the treatment resulted in dose-dependent and time-
dependent re-expression of ERα mRNA [110, 111]. This was speculated to be due to the loss 
of ERα expression or that TSA could potentiate the effect of DNA methyltransferase inhibitors 
such as 5-aza-2-deoxycytidine, treated together on the re-expression of the ERα protein [112]. 
Activation of the silenced ERα by HDAC1 inhibition and partial re-expression of ERα by TSA 
treatment may provide a possible therapeutic treatment for patients with advanced breast 
cancer, restoring estrogen-mediated signaling and growth. Thereby, inhibition of HDAC1 
expression or activity may provide a new strategy for breast cancer therapy.
The phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway plays 
a critical role in multiple cellular functions including metabolism, proliferation, growth, and 
survival [113]. Studies have found PI3K/mTOR pathway to be a promising target in breast can-
cer [114]. The p70 S6 kinase (S6K1) is one of the best-characterized downstream targets of mTOR 
and plays an important role in protein translation and cell proliferation [115]. The mTOR inhibi-
tor rapamycin, tested as an anticancer drug, rapidly dephosphorylates and inactivates S6K1. 
S6K1 is amplified in 10–30% of breast cancer cell lines, and its overexpression is associated with 
poor prognosis in breast cancer patients. PI3K inhibitors are able to regulate the expression of 
ERα through the activity of S6K1, as in cells that have S6K1 overexpression, rapamycin can 
increase both mRNA and protein levels of ERα, promoting the acetylation of its promoter [114].
In some cases, HDAC1 activity and its binding to the ERα promoter is required for the rapamy-
cin-dependent upregulation of ERα expression. Thus, when S6K1 is active and HDAC1 is 
hyper-phosphorylated, it results in decreased expression of ERα, whereas in the presence of 
rapamycin or cell starvation, S6K1 activation and mitogen dependent HDAC1 phosphorylation 
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is ablated, increasing the level of ERα in breast cancer cells. Thus, the mitogen-dependent phos-
phorylation of HDAC1 inhibits the positive transcriptional regulation of the deacetylase on ERα 
expression [116]. Since both HDACs and mTOR inhibitors are known to have anti-proliferative 
effect in breast cancer cells, their combinatorial treatment shows promise (Figure 4).
Figure 4. Mitogen-mediated HDAC1 phosphorylation and ERα transcriptional regulation. PI3K/mTOR pathway is 
activated by the RTK. Subsequently, S6K1 activation controls HDAC1 phosphorylation and thereby reduces acetylation 
of the ERα promoter and gene expression. In the case of cell starvation or when rapamycin is present, S6K1 is not active 
and is not able to phosphorylate HDAC1, promoting acetylation of ERα and its gene expression.
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3.3.1. The role of antiestrogens in epigenetic silencing
Corepressors are associated with deacetylase activity through the recruitment of HDACs, and 
these HDACs possess different functional domains responsible for deacetylase activity and 
interaction with other proteins. The amount of histone acetylation is therefore determined by 
an equilibrium between acetyltransferases and deacetylases, and that the ratio of corepressors 
to coactivators is the modulator of transcription in any given context [112]. The ligand-depen-
dant activation of steroid hormones receptor regulates a variety of gene expression. Binding 
of an agonist leads to the activation of transcription, whereas an antagonist does the opposite, 
leading to inhibition. ERα bound to an anti-estrogen is unable to activate transcription, and 
this may be due to the recruitment of a repressor complex with HDAC activity [117] making 
the use anti-estrogens a feasible treatment option. However, the use of anti-estrogens is limited 
due to the associated side effects or the development of resistance. Moreover, HDAC activity 
has also been associated with gene silencing in some eukaryotes [117]. This gene silencing asso-
ciated with HDAC binding at the ERα promoter could be due to the direct targeting of HDAC 
to estrogen-responsive elements (EREs), thereby mimicking or modulating the effects of the 
anti-estrogens [118]. The specific sites of the action of HDACs are therefore associated with 
the binding of corepressors and in-turn lead to the reversible silencing process, thus a poten-
tial therapeutic option. An example of this phenomenon was highlighted in one of the stud-
ies where treatment of MCF-7 cells with an antiestrogen hydroxytamoxifen (OHT), induced 
silencing of estrogen-responsive genes [118]. Similarly, the estrogen-dependent expression of 
the ERα was partially silenced after 3 months of OHT treatment and OHT-resistant cell growth 
appeared simultaneously. It was found that histone deacetylase activity was involved in the 
repressive effect by its binding to estrogen-responsive elements (ERE) and the antiestrogen 
effect might be very similar, if not identical to the ERE-targeted HDAC activity [118].
3.4. Promoter DNA methylation and signaling pathways
DNA methylation profiles of many genes have been linked with cancer initiation and pro-
gression [119]. As discussed earlier, in the case of DNA methylation, the most extensively 
studied mechanism of epigenetic control is global hypomethylation that leads to genome 
instability. At the same time, hypermethylation of promoter regions has been detected in a 
vast majority of tumor suppressor genes, which are strongly associated with tumor develop-
ment. Hypermethylation events can occur early in tumorigenesis, involving the disruption of 
pathways that may predispose cells to malignant transformation. Gene silencing by hyper-
methylation of promoter genes is an important mechanism of carcinogenesis and has great 
potential for cancer prevention and therapy [120].
In the case of breast cancer, the distribution of aberrantly methylated regions in the genome 
was found to be nonrandom and concentrated in relatively small genomic regions spanning 
up to several hundred kilobases. DNA hypermethylation also leads to aberrant regulation 
of the Wnt pathway in breast cancer, and an overstimulated Wnt signaling is a hallmark of 
different breast cancer tumor subtype [121]. Functional loss of negative Wnt regulators by 
epigenetic gene silencing, through DNA methylation of the tumor suppressor gene-associ-
ated promoters, has been found to contribute to the activation of aberrant WNT/β-catenin 
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signaling [122]. Recent studies have also found impaired regulation of Wnt-antagonists by 
promoter hypermethylation in breast cancer. The growing list of epigenetically silenced WNT 
antagonists involved in human cancers indicates an important role for epigenetic inactiva-
tion events in tumor initiation and progression [123]. For examples, some Wnt proteins like 
WNT1, WNT2 and WNT3A are overexpressed in breast cancer, acting as oncogenic activators 
for canonical Wnt signaling [124]. In contrast, WNT5A acts as a tumor suppressor inhibiting 
tumor cell proliferation, antagonizing the WNT/β-catenin signaling and is thereby silenced by 
tumor-specific methylation [125]. In parallel, epigenetic inactivation of Wnt gene family mem-
bers, WNT7A and WNT9A, through promoter methylation, has been reported as well [126]. As 
epigenetic dysregulation of WNT/β-catenin signaling frequently contributes to tumor patho-
genesis, identification of aberrant epigenetic events that activate WNT/β-catenin signaling 
may provide useful biomarkers for cancer detection and prognosis. Some Wnt proteins like 
Wnt1, Wnt2 and Wnt3A are overexpressed in breast cancer, acting as oncogenic activators 
for canonical Wnt signaling [124]. In addition, WNT5A acts as a tumor suppressor inhibiting 
tumor cell proliferation, antagonizing the WNT/β-catenin signaling and is thereby silenced by 
tumor-specific methylation [125]. In parallel, epigenetic inactivation of Wnt gene family mem-
bers, WNT7A and WNT9A, through promoter methylation, has recently been reported [126]. 
As epigenetic dysregulation of WNT/β-catenin signaling frequently contributes to tumor 
pathogenesis, identification of aberrant epigenetic events that activate WNT/β-catenin signal-
ing may provide useful biomarkers for cancer detection and prognosis.
In addition, hypermethylation of the gene promoters of Wnt repressors was observed in vari-
ous cell lines and tissues. The epithelial adhesion molecule E-cadherin (encoded by CDH1) 
also acts as a negative regulator of WNT/β-catenin signaling by affecting the intracellular 
localization of β-catenin. Epigenetic silencing of CDH1, by promoter methylation has been 
observed in breast cancer, leading to aberrant activation of WNT/β-catenin signaling. The 
APC promoter (adenomatous polyposis coli) of the WNT/β-catenin signaling pathway has 
also been found to be hypermethylated at the CpG island in ~35–50% of breast cancer tumors 
and cell lines [127]. The methylation of APC gene is a cancer-specific change and may disrupt 
the regulation in the APC/β-catenin pathway in breast cancers, making it a common mecha-
nism of the inactivation of tumor suppressor gene in primary breast cancer.
Histone methylation is also known to play a key role in ERα-mediated activation of target 
genes. Recent studies found that histone demethylase KDM1 and ERα coregulator proline-, 
glutamic acid- and leucine-rich protein-1 (PELP1) plays a role in regulating histone methyl 
marks at ERα target genes [128]. PELP1 deregulation alters histone methylation at ERα target 
genes, contributing to hormone-driven tumor progression and resistance to treatment.
3.4.1. The synergistic role of HDACs and DNA methylation in breast cancer
Patients who have ER-negative breast cancer seldom respond to endocrine therapy. One of 
the mechanisms to explain the loss of estrogen receptors expression is the methylation of cyto-
sine at the 5′ regulatory region of the gene at the CpG island [133]. CpG island in ERα genes 
is highly methylated in ER-negative breast cancer but remain unmethylated in normal breast 
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tissue and many ER-positive tumors as well as ER-positive cancer cell lines. This abnormal 
methylation pattern could account for transcriptional inactivation of the ER gene and subse-
quent hormone resistance in some human breast carcinomas. The functional importance of 
this finding is demonstrated by the fact that treatment of ER-negative human breast cancer 
cells with the demethylating agent, 5-aza-2′-deoxycytidine (AZA), led to reactivation of ER 
mRNA and functional ER protein [129].
An abundant chromosomal methyl CpG-binding protein was the first protein identified to 
link methylated DNA and a HDAC-containing transcriptionally repressive complex for gene 
silencing. More recently, the well-known maintenance methyltransferase, DNMT1, was found 
to interact physically with HDAC through its N terminus, thereby leading to a transcription-
ally inactive complex that represses transcription [130]. Thus, the loss of ER expression in 
some breast cancers is associated with transcriptional repression through HDAC activity on 
the methylated ER gene, linking HDAC activity closely to DNA methylation of ERα promoter 
and thereby helping in understanding the associated resistance to endocrine therapy.
Recent studies also demonstrated that combination therapy involving HDAC inhibitors with 
DNA methyltransferase-1 (DNMT1) inhibition is synergistically effective in inducing apopto-
sis, differentiation and/or cell growth arrest in many cancer types including breast cancer. The 
combination was also synergistic in inducing re-expression of ERα in ERα-negative breast 
cancer cells. Expression of ERα is induced by 5-aza-2′-deoxycytidine (DNMT1 inhibitor) and 
trichostatin A (HDAC inhibitor) in ER-negative breast cancer. Studies at the preclinical level 
indicate that sensitivity of ER-negative breast cancer cells could be restored to endocrine 
therapy by the use of AZA and TSA both in vitro and in vivo. When HDAC inhibitors such 
as vorinostat were used in combination with decitabine, the capacity of breast cancer cells to 
proliferate and to form colonies was inhibited significantly as compared to when either drug 
was used alone [146]. Histone methylation could also be a druggable target as some therapeu-
tic benefits have been observed during the preclinical studies.
4. Coding and noncoding RNAs in breast cancer
4.1. Current techniques for detection of breast cancer
The genetic signature identified from gene expression arrays has been incorporated into five 
different breast cancer prognostic platforms. As an improvement over the classical ER/PR/
HER2 status, a panel of eight genes has been identified to classify the different breast cancer 
subtypes [131]. This panel includes the genes ER, PR, HER2, CK5, CK14, p53, MKI67 and 
EGFR. Cytokeratin 5 (CK5) and cytokeratin 14 (CK14) genes expressed by basal/myoepithelial 
cells are used to characterize basal-like TNBC [132]. EGFR is frequently upregulated in TNBC 
cases with a basal phenotype and can be targeted for therapy. Ki-67 is a marker for prolifer-
ating cells. Ki-67 and p53 expression can be used to distinguish Luminal A from Luminal B 
tumors. The different prognostic tests for breast cancer, namely, the 21-gene Oncotype DX® 
[133], 70-gene MammaPrint® [134], and 50-gene PAM50 [135] detect the presence of these vari-
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ous mRNA biomarkers in patient samples. The need for additional markers for breast cancer 
subtype classification and further treatment regime arises from the observation that while 
Oncotype Dx and MammaPrint are the only FDA-approved RNA-based assays, they only 
share one gene in common (MKI67), besides ER and HER2.
Less than 2% of the human genome is translated into proteins. However, around 97% of 
the genome is transcribed, indicating that most of transcripts are not translated. Initially 
described as “transcriptional noise,” increasing evidence in the past few years has helped 
identify the regulatory functions of these “noncoding RNAs.” Noncoding RNAs are clas-
sified as small noncoding RNAs and long noncoding RNAs (lncRNAs). Small noncoding 
RNAs include miRNAs, small-interfering RNAs (siRNAs) and piwi-interacting RNAs mea-
suring <200 nt in length. LncRNAs as the name suggests are “long,” ranging in length from 
200 nt to 200 kb. Noncoding RNAs, both small and long, have been shown to regulate criti-
cal cellular functions such as transcriptional and posttranscriptional regulation which in 
turn modulate cell growth and differentiation [136]. Thus, it is no surprise that the aberrant 
expression of several noncoding RNAs has been observed and attributed to various diseases, 
including cancer.
Given that noncoding RNAs comprise the vast majority of the human transcriptome and 
evidence of their essential role in gene regulation, it is important that this largely unex-
plored class of molecules be studied in the cancer context more closely. Some miRNAs 
and lncRNAs implicated in breast cancer initiation, progression and metastasis have been 
summarized in Figure 5.
4.2. MiRNAs in breast cancer
MiRNAs are 18–24 nt in length noncoding RNA molecules that regulate gene expression by 
mRNAs degradation or inhibition of protein synthesis. MiRNAs have been shown to regu-
late numerous physiological processes such as differentiation, development and cell death as 
well as pathophysiological processes such as cancer biology, progression and prognosis. The 
aberrant expression of miRNAs in cancers can lead to an abnormal expression of their target 
genes thereby contributing to cancer etiology. Mounting evidence suggests a significant role 
of miRNAs in breast cancer classification, prognosis, as potential biomarkers for disease pro-
gression as well as treatment [137].
4.2.1. MiRNAs and breast tumor initiation
Mammary gland epithelia comprise different cells including mammary stem cells (MaSCs)/
basal cells, luminal progenitors and mature luminal cells. Several subtypes have been described 
among breast cancers, including claudin-low, basal, luminal, normal-like and ERBB2-enriched 
subtypes. These distinct molecular subtypes derive from different “cells of origin,” that is, cells 
that acquire the first oncogenic events in the initiation of breast tumorigenesis [138, 139]. The 
close association between cell lineage targeting and the resulting cancer phenotype suggests that 
lineage-restricted mechanisms that normally operate during the mammary gland development 
and homeostasis may contribute to tumorigenesis. Some miRNAs have been recently identified 
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Figure 5. MiRNAs and lncRNAs implicated in breast cancer initiation, progression and metastasis. Several miRNAs 
and lncRNAs controlling key oncogenes such as HMGA2 among others are downregulated in the breast cancer stem 
cells (BCSCs) leading to proliferation and self-renewal of these cells and breast cancer progression. Downregulation of 
tumor suppressor miRNAs such as the miR-200 family leads to an upregulation of the EMT markers ZEB1 and ZEB2, 
thus aiding tumor proliferation and invasion. A number of mRNA markers are displayed by tumor cells at this stage 
aiding in their subtyping and prognosis. Additionally, several noncoding RNA biomarkers have also been identified 
including noninvasive circulating ncRNAs which closely correlate with patient prognosis. Further, several miRNAs and 
lncRNAs contribute to the hormonal resistance displayed by breast cancer cells via targeting tumor suppressors such as 
PTEN, cell cycle genes such as p27 or members of the hormone signaling pathways such as ERα, thereby leading to more 
aggressive and metastasized cancer. Currently, a number of novel and safe therapeutic options are being researched to 
aid the conventional treatment options to help ameliorate breast cancer.
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as potential “keepers” of this lineage-restricted identity. Thereby, aberrant expression of these 
miRNAs has been implicated in breast cancer molecular subtypes. Unique miRNA signatures 
characterize each step of the mammary differentiation hierarchy in the normal mammary gland 
(MaSCs/basal cells, luminal progenitors, mature luminal and stromal cells). MiRNA networks, 
also known as miRNome, are responsible for governing lineage commitment and cellular differ-
entiation in the mammary tissue. MiRNAs act by targeting lineage-specific mRNAs thus regu-
lating lineage-specific gene expression [140]. For example, the expression of miRNAs implied 
in MaSCs functions and pathways (WNT, NOTCH and Polycomb groups) such as miRNA-
10a, miRNA-200a/b, miRNA-203 and miRNA-148a is restricted to the luminal subpopulation. 
Conversely, miRNA-146a, miRNA-221/222 and miRNA-205, known to regulate genes expressed 
in the luminal lineages (BRCA1, GATA3, KIT and ELF5), are restricted to the MaSCs population. 
Integrating these miRNA signatures with both transcriptomics and histone marks analysis has 
revealed that key developmental miRNAs are epigenetically regulated by global changes in 
histone methylation during differentiation [140]. By comparing miRNA signatures of normal 
breast epithelial cells with breast tumors, many miRNA-mRNA networks deregulated in cancer 
cells have been identified. Therefore, these miRNAs may potentially represent new biomarkers 
and targets. Furthermore, the miRNome of breast tumors allows the classification of tumors into 
molecular subtypes and can predict the patient’s outcome [141–143].
4.2.2. Oncogenic and tumor suppressor-like miRNAs in breast cancer
Due to amplification of chromosomal regions of miRNAs, certain miRNAs may be overex-
pressed in cancer. If these miRNAs target TSGs, it would downregulate the TSGs leading 
to malignant growth. Hence, such potentially cancer-causing miRNAs are called oncomiRs. 
Conversely, oncosuppressor miRNA genes are frequently located in fragile loci, which are 
hotspots for deletions, mutations and promoter methylation. Genetic aberrations in such loci 
may result in downregulated miRNA expression and a concomitant increase in expression of 
oncogenes. These alternations of miRNA lead to tumor formation by inducing cell prolifera-
tion, invasion, loss of apoptosis, and angiogenesis. Thus, miRNAs can act both as oncogenes 
as well as TSGs [144, 145].
4.2.2.1. OncomiRs in breast cancer
MiR-21 is a prominent oncomiR which is upregulated in breast cancer. The targets of miRNA-
21 include BCL-2 (regulates apoptosis), PTEN (regulates cell survival) and PDCD4, TPM1 and 
MASPIN  (involved in tumor progression, invasion and metastasis). Thus, overexpression of 
miR-21 in breast cancer supports tumor growth [146, 147]. MiR-155 is an oncomiR, with an 
increase in expression in breast cancer, where it targets tumor suppressor gene SOCS1 [148].
4.2.2.2. Tumor suppressor-like miRNAs in breast cancer
Let-7 is an important tumor suppressor miRNA with a decrease in expression in breast 
cancer. It targets the Ras pathway and regulates cell proliferation, adhesion and migration 
[149]. Targets of let-7 include HMG2A (responsible for maintenance of stemness of stem 
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cells), lin-28 and PEBP1 (oncogenes involved in cancer progression and metastasis) [150, 
151]. Thus, a loss of let-7 leads to an upregulation of these oncogenes resulting in breast 
cancer stem cell renewal and cancer progression.
4.2.3. MetastamiRs in breast cancer
Metastasis is a complex multistep process, which includes the formation of tumors at sites dis-
tant from the primary site of the cancer. The term ‘metastamiR’ refers to as a metastasis-asso-
ciated miRNA [152]. Several miRNAs such as miR-10b, miR-21, miR-30a, miR-30e, miR-125b, 
miR-141, miR-200b, miR-200c and miR-205 have been implicated in controlling metastasis 
in breast cancer [152]. Different metastamiRs have been shown to both promote and inhibit 
metastasis and regulate key steps in the metastatic program. Key players of the miRNA bio-
genesis pathway are also targeted by miRNAs thereby controlling metastasis. For instance, 
in breast cancer patients, it was found that miR-103/107 family targets Dicer1 to decrease its 
expression, and as a consequence, several miRNAs were downregulated [153].
4.2.3.1. MetastamiRs (metastasis-promoting miRNAs)
MiR-21 is a metastamiR targeting several TSGs in breast cancer. MiR-21 downregulates TSGs 
PDCD4, TPM1 and MASPIN  to increase breast cancer invasiveness and metastasis [146, 147, 
154]. MiR-10b is an example of another oncomiR, which induces invasion and metastasis 
in breast cancer xenograft models when overexpressed in nonmetastatic breast tumors [33, 
155–157]. MiR-373 and miR-520c are able to initiate breast cancer cell migration and invasion 
in vitro and in vivo, which implicates these miRNAs as metastasis-promoting miRNAs [158]. 
It has been shown that miR-22 targets TIP60 (HIV-1 Tat interacting protein), a lysine acetyl 
transferase, in breast cancer and stimulates the expression of EMT genes. Furthermore, analy-
sis of gene expression and survival data from the TCGA dataset and gene expression omnibus 
(GEO) database revealed that patients with high TIP60 and low miR-22 expression were asso-
ciated with good survival, whereas patients with low TIP60 and high miR-22 levels showed 
poorer prognosis for survival. This suggests that TIP60 and miR-22 could act as prognostic 
marker in breast cancer disease progression and that targeting the TIP60–miR-22 axis could 
lead to an effective therapeutic strategy for metastatic breast cancer [159].
4.2.3.2. Metastasis-suppressing miRNAs
Tavazoie et al. [160] demonstrated that restoring the expression of those miRNAs whose 
expression is lost in malignant breast cancer cells suppresses lung and bone metastasis in 
metastatic breast cancer. Restoration of expression of miR-335 inhibited metastatic cell inva-
sion while miR-126 restoration reduced overall tumor growth and proliferation.  MiR-146a 
and b target IRAK1 and TRAF6 to down regulate NF-κB signaling and inhibit invasion and 
migration of breast cancer cells [161]. MiR-497, whose expression is downregulated in breast 
cancer samples, has been shown to induce apoptosis of breast cancer stem cells (BCSCs) by 
targeting Bcl-w. Additionally, its expression has been shown to be negatively correlated with 
tumor size, metastasis stage and HER2 status in breast cancer [162]. EMT is an important 
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property of malignant cancer cells wherein the epithelial cells lose cell-cell contact allowing 
them to be motile and thus metastasize to distant organs. The miR-200 family is known to 
regulate EMT by targeting the EMT markers, CDH1or E-Cadherin, a marker for epithelial 
phenotype, vimentin, ZEB1, which regulates EMT as seen in in vivo studies by promoting 
metastasis of tumor cells in mouse model [163, 164] and ZEB2, which are expressed in mes-
enchymal cells and thus mark the mesenchymal phenotype [165]. Furthermore, it has been 
shown that ZEB1 regulates EMT in human breast cancer by promoting metastasis of tumor 
cells in mouse model [163, 164]. The miR-200 family by targeting ZEB1 and ZEB2 down-
regulates their expression, thereby tipping the balance toward the epithelial phenotype [165, 
166]. Gregory et al. Demonstrated that the miR-200b family is downregulated in response 
to the cytokine, transforming growth factor-β (TGF-β), which induces EMT. The authors 
further demonstrated that ectopic expression of the miR-200 family is able to inhibit EMT, 
thereby affecting breast cancer progression [167].
4.2.4. Regulation of signaling pathways by miRNAs in breast cancer
4.2.4.1. ER signaling
Among the two classes of estrogen receptors, the estrogen receptor-α (ERα) is overexpressed 
in approximately 75% of breast cancer cases. Increased signaling through ERα in mammary 
stem cell induces continuous replication of these cells, thereby increasing the risk of tumori-
genesis. Tumor-suppressive miRNAs, such as miR-145 [168], miR-17/20 family, miR-193b, miR-
206 and mir-302c, inhibit the ER signaling activated proliferation of mammary epithelia, by 
targeting either the ER receptor α or its coactivator AIB1 [169, 170]. MiR-206 is upregulated in 
ER-negative breast cancer but downregulated in ER-positive breast cancer [171]. MiR-17-5p 
targets AIB1, a coactivator of ERα [172]. The let-7 family of miRNAs is known to regulate the 
expression of both ERα66 and ERα36 (a novel short form of the ERα protein) in breast can-
cer. In breast cancer, let-7 is known to be downregulated, resulting in an upregulation of its 
targets, ERα66 and ERα36. ERα66 is predominantly nuclear in expression, where it regulates 
the transcription of c-Myc, CCND1 and pS2, while ERα36 activates MAPK/ERK signaling path-
way. Overexpression of let-7 miRNAs can negatively regulate these pathways by inhibiting the 
phosphorylation of ERK and Akt. Further, ERα36 protein levels were found to be upregulated 
in a tamoxifen-resistant MCF-7 breast cancer cell line, indicating that ERα36 might play a role 
in mediating resistance to tamoxifen therapy in breast cancer. However, overexpression of the 
let-7 family members in tamoxifen-resistant MCF-7 cells significantly decreased ERα36 protein 
level further increasing tamoxifen sensitivity in these cells [173]. These studies demonstrate the 
regulation of the ER signaling pathway and development of tamoxifen resistance in breast can-
cer by let-7 miRNAs, hence hinting at the possibility of developing novel therapeutic strategies.
4.2.4.2. HER2 (ERBB) signaling
In breast cancer, ERBB2/HER2 is found to be amplified and/or overexpressed in up to 30% of 
patients, correlating with poor prognosis. Further, abnormal HER signaling induces cell pro-
liferation [174]. HER2 and HER3 are targeted by miR-125a/b thereby inhibiting breast cancer 
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growth [175]. HER3 receptor is also targeted by miR-205 inducing cell cycle arrest thereby 
inhibiting cell proliferation in breast cancer [176].
4.2.5. MiRNAs regulating breast cancer stem cells
Human breast cancer stem cells (BCSCs) were first isolated by Al-Hajj et al. [177] as cells dis-
playing a different set of cell surface markers CD44þ/CD24/low as compared to normal mam-
mary gland stem cells. Comparison of BCSCs with normal mammary stem cells revealed a 
differential expression of miRNAs. MiR-200c, let-7, miR-30 and miR-34 were observed to be 
downregulated, whereas miR-181 and miR-495 showed an increased expression in BCSCs. 
Let-7 inhibits the stem cell self-renewal in both normal and CSCs of breast and the down-
regulation of let-7 in breast cancer, thereby leading to the formation of BCSCs by unchecked 
self-renewal and undifferentiated status of mammary gland stem cells [60]. Moreover, let-7 
is also known to target many oncogenes such as HMGA2, k-Ras, p-RAS and ERK, which are 
highly expressed in BCSCs [149, 150, 178]. These oncogenes further support the formation 
and maintenance of BCSCs via self-renewal and maintenance of undifferentiated status of 
BCSCs [178]. In BCSCs, miR-30 is downregulated 30 fold, leading to increased expression of 
its targets: ubiquitin conjugating enzyme 9 (Ubc9) and integrin β 3 (ITBG3), and promoting 
the self-renewal ability of BCSCs. Specific knockdown of miR-30 induced differentiation of 
BCSCs, suggesting that miR-30 regulates self-renewal and tumorigenicity of breast cancer 
[179]. Furthermore, three families of miRNAs, namely, miR-200c-141, miR-200b-200a-429, 
and miR-183-96-182 are known to be downregulated in human BCSCs, normal human and 
murine mammary stem/progenitor cells, and embryonal carcinoma cells. MiR-200c affects 
breast cancer proliferation by modulating the expression of BMI1, which regulates the self-
renewal of stem cells. Furthermore, miR-200c has been shown to inhibit the development of 
normal mammary stem cells into mammary ducts as well as the ability of human BCSCs to 
form tumors in vivo [180].
4.2.6. MiRNAs resulting in breast cancer therapy resistance
Several miRNAs have been described as controlling genomic stability of breast cancer 
cells. DNA double-strand breaks are lesions induced by ionizing radiation (IR) and can 
be efficiently repaired by DNA homologous recombination, a system that requires RAD51 
recombinase. Overexpression of miR-155 in human breast cancer cells reduces the level 
of RAD51 and affects the cellular response to IR. Consequently, tumors overexpressing 
miR-155 are sensitive to radiation therapy. Furthermore, high miR-155 levels are associated 
with lower RAD51 expression and with better overall survival of patients in a large series 
of triple-negative breast cancers [181]. Other miRNAs have also been shown to sensitize 
breast cancer cells to chemo/radio sensitivity. The tumor suppressor p53 whose expression 
is affected by DNA damage and oncogenic stress, is the direct inducer of miR-34a [182]. It 
has been observed that elevated expression of miR-34a in a HER-2 positive breast cancer 
cell line (UACC-812) contributes to increased resistance to ionizing radiation as opposed to 
MDA-MB-231 expressing low levels of miR-34a. Thus, while the mechanism is unknown, in 
p53-mutant breast cancers, inhibition of miRNA-34a enhances radio sensitivity [183]. Also, 
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miRNA-182 controls DNA repair of breast cancer cells by targeting BRCA1, and inhibition 
of miRNA-182 leads to resistance to PARP inhibitors (poly ADP ribose polymerase) [184]. 
Because the BRCA pathway controls mammary stem cell fate, it is possible that overexpres-
sion of miR-182 in breast cancer stem cells would sensitize this radio-resistant cell popula-
tion to radiation therapy. Anti-estrogen therapies are given to the patients with ER-positive 
breast tumors. Despite initial response, 25% of primary tumors and almost all metastatic 
tumors will develop resistance. MiRNA-221/222 are key regulators of hormonal resistance 
of breast cancer stem cells. MiRNA-221/222 act through diverse mechanisms by targeting 
ERα, by upregulating β-catenin and the TGF-β pathway [185] or by targeting the cell-cycle 
inhibitor p27 [186]. Finally, 15–20% of breast tumors display an overexpression of the ERBB2 
oncoprotein. ERBB2 overexpression promotes the expansion of the breast cancer stem cells 
through the activation of a PI3K/AKT/GSK3β/WNT signaling. ERBB2-positive tumors can 
be treated with several targeted therapeutics. MiRNA-21 plays a role in the resistance dis-
played by ERBB2-positive tumors to trastuzumab, by targeting the PTEN tumor suppres-
sor. The authors further show that knockdown of miR-21 could restore PTEN levels thus 
sensitizing the cells to anti-HER-2 therapy [187]. MiRNA-205 regulates the ERBB3 recep-
tor [188]. ERBB3 transactivates ERBB2, and both receptors trigger the PI3K/AKT signaling 
pathway. ERBB2/ERBB3 interaction could lead to anti-ERBB2 resistance of breast tumors. 
However, miR-205 is downregulated in breast cancer. Thus, restoration of miRNA-205 in 
breast tumors could help overcome resistance to anti-ERBB2 therapy.
4.2.7. Potential prognostic value of miRNAs
Several studies have evaluated the role of specific miRNAs in breast cancer spread and sur-
vival. A screen identified five upregulated miRNAs (miR-30b, miR-148a, miR-150, miR-450a 
and miR-155) and six downregulated miRNAs (miR-24, miR-99a, miR-99b, miR-125b, miR-
130b and miR-205) in primary breast cancer tumors versus corresponding lymph nodes [189]. 
Further, miR-373 was identified as being overexpressed in lymph-node metastases as com-
pared to primary tumors [158], indicating the prognostic value of these miRNAs. Other miR-
NAs such as miR-187 [190], miR-27b and miR-103/107 [191] have also been found to have 
a prognostic value in breast cancer. Moreover, in ER-positive lymph node-negative (LNN) 
breast cancer patients, 12 miRNAs have been identified with early relapse versus late relapse 
(miR-205, miR-22, miR-516-3p, miR-7, miR-34b, miR-151, miR-210, miR-193b, miR-489 miR-
449, miR-145 and miR-128a). Indeed, four of these 12 miRNAs (miR-7, miR-128a, miR-210 and 
miR-516-3p) have been positively linked to breast cancer aggressiveness while miR-210 has 
also been associated with metastatic ability of TNBC [192].
4.2.8. MiRNAs as breast cancer biomarkers
4.2.8.1. MiRNA expression from tissue biopsies
MiRNAs can serve as biomarkers for breast cancer based on their expression profile from 
RNA sequencing or tissue microarray assays. This can be achieved by mapping the global 
mRNA and miRNA expression from tumor tissues using high-throughput platforms, such as 
microarray chips and deep sequencing. Also, other techniques such as in-situ hybridization 
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(ISH) can be used to detect mRNAs and miRNAs from fresh frozen or archived paraffin-
embedded (FFPE) tumor tissue samples and protein expression can be evaluated using immu-
nohistochemistry (IHC) [193]. The use of miRNA biomarkers has several advantages over 
protein coding genes: (1) miRNAs are more stable than mRNA and thus enable easier and 
reliable detection in FFPE samples (2) the presence of mere 1000 miRNAs makes the human 
miRNome much easier to screen and evaluate with less demanding bioinformatic analysis 
than the mRNA transcriptome [194]. The expression of a number of miRNAs closely corre-
lates with the ER, PR and HER2 status in breast cancer, highlighting their use as biomarkers 
of disease progression and treatment response [141, 195]. MiR-210 has been validated as a 
prognostic biomarker in breast cancer since elevated miR-210 levels have been associated with 
poor outcome both in ER-positive and ER-negative cases [196]. Moreover, miR-210 has been 
developed to predict outcome in ER-positive cases that received adjuvant tamoxifen treatment 
for 5 years [197]. Other miRNA biomarkers include miR-205, which is used as a prognostic 
marker for the triple negative (TN) subtype since a positive correlation has been observed 
between miR-205 expression and favorable clinical outcome in TN cases [198].
4.2.8.2. Circulating miRNAs as breast cancer biomarkers
Circulating miRNAs are ideal for clinical use, since they are highly stable and can be detected 
by a noninvasive manner in a blood sample. Serum or plasma miRNAs have been shown to be 
resistant to RNases and DNases thus are more stable than their cellular counter parts as well as 
mRNAs. Serum and plasma miRNAs can be easily isolated and quantified by RT-qPCR analy-
sis. Moreover, specific miRNAs have also been demonstrated as being indicative of the breast 
cancer stage and/or ER/PR status. Numerous studies have documented the presence and quanti-
fied serum miRNAs from breast cancer patient samples. Asaga et al. assayed circulating miR-21 
of 102 breast cancer patients and 20 healthy controls and found higher concentrations in these 
patients, especially in metastatic cases [199]. A study that quantitatively profiled the expression 
of seven miRNAs by real-time PCR, in tissue and blood samples of patients with breast cancer 
at different clinical stages and age-matched healthy individuals found that, while the expression 
of two miRNAs, miR-195 and let-7a was significantly higher in blood samples of breast cancer 
patients in comparison to control subjects, their circulating levels remarkably decreased after 
surgical resection in a subset of 29 cases, reaching levels comparable with control subjects [200, 
201]. 26 circulating miRNAs with two-fold differential expression have been identified from the 
plasma of early stage breast cancer patients as compared to healthy controls [202].
This mounting evidence generates the hypothesis for a signature of circulating miRNAs that 
could be a reliable biomarker for disease progression.
4.2.9. MiRNA therapeutics in breast cancer
4.2.9.1. AntagomiRs and anti-miRNA oligonucleotides targeting oncomiRs and metastamiRs
The most common miRNA therapeutic approach to inhibit the functions of miRNAs involve, 
targeting by using antisense miRNAs (antagomiRs) capable of knocking down these miR-
NAs. AntagomiRs are synthetic RNA molecules with favorable stability, resistance to RNase 
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and pharmacologic properties that allow in vivo miRNA inhibition [203]. MiRNA knock-
down therapy can be used in conjunction with chemotherapy to facilitate knockdown of 
oncomiRs along with concomitant targeting of the proliferating cells using anticancer drugs. 
Knockdown of miR-10b using sequence-specific antagomiRs led to an upregulation of its tar-
get mRNA Hoxd10. However, the use of miR-10b antagomiRs did not reduce primary mam-
mary tumor growth in animal model but was successful in suppressing the formation of lung 
metastases. Furthermore, miR-10b antagomiR does not induce toxicity in healthy mice and 
thus can be a safe therapeutic option [204]. Moreover, knockdown of miRNAs by anti-sense 
approach also sensitizes cancer cells to chemotherapeutic drugs as in the case of miR-21, the 
knockdown of which sensitized MCF7 cells to the chemotherapeutic agent and topoisomer-
ase inhibitor, topotecan [205].
Another approach of ablating miRNAs function is by using anti-miRNA oligonucleotides 
(AMOs) with 2-O-methyl groups and AMOs based on locked nucleic acid (LNA). AMOs are 
stable synthetic antisense oligonucleotides that can rapidly, selectively and irreversibly bind 
endogenous miRNAs, sequester and make them functionally inactive [206, 207]. Targeting 
oncomirs via either antagomiRs or AMOs has been demonstrated to reduce cancer cell prolif-
eration and metastasis [79], sensitization to chemotherapeutic agents [80], hormone therapy 
[52] and anti-HER2 therapy [71] in breast cancer cell lines.
In addition to knocking down miRNAs, upregulating the expression and activity of tumor 
suppressor miRNAs has potential in ameliorating breast cancer. Tumor suppressor miRNAs 
can be upregulated using miRNA mimics, which are synthetic molecules with short dou-
ble-stranded synthetic oligonucleotides with sequence similarity to the particular miRNA 
under consideration. Overexpression of TS miRNAs using miRNA mimics has been shown 
to decrease cancer cell proliferation as well as induce chemosensitivity in breast cancer cell 
lines [208, 209].
4.2.9.2. Peptide nucleic acids (PNA)
Peptide nucleic acid (PNA) is an artificially synthesized oligonucleotide similar to DNA and 
RNA with a backbone consisting of repeats of 2-aminoethylglycine units [210]. The absence 
of phosphate groups renders a neutral charge to the PNA resulting in stronger and specific 
bonds between complementary PNA/DNA and PNA/RNA as compared to DNA/DNA or 
RNA/RNA. Owing to its synthetic nature, PNA is resistant to degradation by DNases and 
proteases leading to increased intracellular stability. Inactivation of miR-221 with PNA has 
been successful in aggressive breast cancer cell lines where miR-221 is overexpressed [211]. 
An anti-miR-221 PNA (R8-PNA-a221) conjugated with polyarginine-peptide (R8) could inac-
tivate miR-221 and upregulate its target mRNA, p27/Kip1. R8-PNA-a221 displayed efficient 
uptake within target cells without using transfection reagents. To assess the potential of PNA-
anti-miR-221 on inhibition of breast cancer in vivo, MCF-7 cells treated with PNA-anti-221 or 
control PNAs were injected in nude mice [212]. Tumor formation was observed only in 60% 
of mice treated with anti-miR-221 therapy as compared to control. These studies highlight the 
potential of PNAs as anti-tumor therapeutics.
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4.3. Long noncoding RNAs in breast cancer
Long noncoding RNAs are endogenous RNA molecules with a mature length of more than 
200 bases that do not code for functional proteins [213]. LncRNAs are epigenetic regulators, 
and they control gene expression at both the transcriptional and posttranscriptional levels. 
LncRNAs utilize a variety of mechanisms to regulate gene expression. They can recruit chro-
matin modifiers to impair access to targeted genes, they can act as scaffolds to assemble com-
plexes that do not have interacting domains, they can interact with transcription factors to 
directly regulate gene expression, and they can serve as ‘miRNA sponges’ to trap miRNAs 
and regulate translation. Moreover, lncRNAs can be involved in the regulation of the expres-
sion of either their neighboring genes in cis or more distant genes in trans. LncRNAs act as 
coactivators, binding to transcription factors and enhancing their transcriptional activity [214].
4.3.1. Oncogenic LncRNAs in breast cancer
H19 is among the first discovered lncRNAs and displays elevated expression in breast cancer 
[215]. This upregulation of expression is on account of increased binding of the transcription 
factor E2F1 factor to H19 promoter. H19, in turn, promotes cell proliferation in MDA-MB-231 
cells in vitro [216] and also accelerates tumor growth in vivo in animal model [217], possibly 
by repressing tumor suppressor genes such as caveolin-1 [218].
HOTAIR is remarkably overexpressed in metastatic breast cancer. Upregulated HOTAIR in 
breast cancer cells provides a scaffold for PRC2 and LSD1-CoREST (lysine-specific demethyl-
ase-1 with its corepressor protein CoREST (RE1 silencing transcription factor/neural-restric-
tive silencing factor)). PRC2 binds to the 5′ region of HOTAIR while LSD1-CoREST binds to its 
3’ region. This complex regulates the histone modifications H3K27me3 and H3K4me2 at the 
promoters of metastasis suppressing genes such as PCDH10, PCDHB5 and JAM2. As a result, 
these metastasis suppressor genes are silenced; thereby contributing to HOTAIR-induced 
breast cancer metastasis. Indeed, overexpression of HOTAIR in breast cancer cell lines has 
been observed to increase their invasiveness both in vitro and in vivo. Furthermore, knock-
down of HOTAIR has been shown to attenuate EZH2-induced invasion, in benign immortal-
ized breast cells overexpressing EZH2 [219]. Upregulated HOTAIR levels in primary breast 
tumor are an indicator of metastasis thus identifying HOTAIR as an important prognostic 
factor for breast cancer [220].
Urothelial cancer–associated 1 (UCA1) has been identified as an oncogene in breast cancer. 
Huang et al. demonstrated the oncogenic role of UCA1 in breast cancer, in part through sup-
pression of p27. UCA1 competes with p27 mRNA to form a ribonucleoprotein complex with 
hnRNP I (heterogeneous nuclear ribonucleoprotein I) thereby increasing UCA1 stability and 
decreasing p27 protein levels, hence leading to increased proliferation of breast cancer cells 
[221]. Further, UCA1 has been shown to bind to and sequester miR-143 thus decreasing its 
expression in invasive breast cancer cell lines. MiR-143 is known to target and regulate the 
expression of ERBB3. Hence, it is possible that UCA1 increases breast cancer cell proliferation 
by deregulating miR-143–based ERBB3 repression [222].
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MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) or NEAT2 is a conserved 
nuclear noncoding RNA. The role of MALAT1 in breast cancer was controversial with reports 
indicating an oncogenic role by promoting cell proliferation, migration and invasion dur-
ing breast cancer development [223] while a loss of MALAT1 was shown to promote EMT 
via phosphatidylinositide-3 kinase-AKT pathways on MALAT1 [224]. Recently, Arun et al. 
demonstrated an oncogenic role of MALAT1 in breast cancer where knockdown of MALAT1 
using antisense oligonucleotides (ASOs) in a mouse model resulted in slower tumor growth 
and a reduction in metastasis. Thus, knockdown of MALAT1 using ASOs represents a viable 
therapeutic option in breast cancer [225].
SRA (steroid receptor RNA activator protein) gene generates both a coding as well as noncoding 
form of SRA RNA [226]. The noncoding (lnc) SRA RNA is significantly upregulated in breast 
cancer tumors [226], especially in PR-positive tumors [227] and in aggressive and invasive breast 
cancer cell lines (MDA-MB-231 and MDA-MB-468) [228]. LncSRA acts as a scaffold in assem-
bling coregulator complexes by interacting with and coactivating several nuclear receptors (ste-
roid and nonsteroid) and other transcription factors. This hints to a possibility of lncSRA aiding 
in the transcription of key oncogenes in breast cancer. Thus, it was no surprise that knockdown 
of SRA in MDA-MB-231 cells reduced cell invasion along with a downregulation of the genes 
associated with this phenotype. Moreover, depletion of lncSRA in MCF7 cells exhibited a similar 
response with a decrease in the genes responsible for invasion and metastasis [229].
Long stress-induced noncoding transcripts (LSINCTs) are a group of lncRNAs upregulated in 
breast cancer tumor tissues and cell lines. LSINCT5 has been shown to mediate cellular prolifera-
tion and is aided by lncNEAT-1 and PSPC1 (Paraspeckle Component 1) in breast cancer [230, 231].
4.3.2. Tumor suppressor LncRNAs in breast cancer
The lncRNAs that are downregulated in cancer and whose enforced expression is associ-
ated with the suppression of cell proliferation or cell death are termed as tumor suppressor 
lncRNAs.
Maternally expressed gene 3 (MEG3) is a tumor suppressor lncRNA with a decrease in expres-
sion in breast cancer, especially in the most aggressive TNBC subtype [232, 233]. MEG3 forms 
a RNA-DNA triplex structure to regulate the TGF-β pathway genes in breast cancer cells 
[234]. Since TGF-β is an inducer of EMT and invasiveness in breast cancer, inhibition of this 
pathway via MEG3 could present a therapeutic opportunity to control breast cancer. MEG3 is 
also known to reduce breast cancer proliferation and invasion by indirectly modulating p53 
activity. MEG3 regulates MDM2 (mouse double minute 2 homolog) leading to accumulation 
of p53 levels in breast cancer cell lines. This p53 could in turn bind to the promoters of its 
target genes and metastasis suppressors p21, MASPIN  and KAI1 inhibiting migration and 
invasion of MCF-7 breast cancer cells [232].
GAS5 (growth arrest specific 5), in breast cancer, the expression level of GAS5 has been 
shown to be significantly reduced in tumor samples as compared to surrounding normal 
breast epithelia [235]. This decrease in GAS5 expression was observed in grade I and II breast 
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cancer patients, indicating that the GAS5 downregulation is an early event in breast cancer 
progression. Further, this observation also indicates that GAS5 expression may be used as a 
biomarker to predict cancer stage. GAS5 has additional roles in drug resistance and will be 
discussed in the next part.
NKILA (NF-κB interacting lncRNA) binds to the NF-κB/IKB complex masking the phosphor-
ylation site on IKB. Thus, IKK is unable to phosphorylate IKB resulting in IKB remaining 
bound to NF-κB, rendering NF-κB inactive. Expression of NKILA was observed to increase 
apoptosis and reduce invasion in MDA-MB-231 cells. Moreover, ectopic expression of NKILA 
decreases invasion and metastasis in breast cancer mouse models. Also, low NKILA expres-
sion is associated with poor patient prognosis [236]. Thus, inhibiting NF-κB through NKILA 
may be a mechanism to suppress breast cancer metastasis.
4.3.3. LncRNAs and breast cancer stem cells
A number of lncRNAs have been implicated in maintaining stemness of breast cancer stem 
cells, thus promoting the spread of the cancer. The lncRNA HOTAIR has been shown to 
downregulate miRNA-7 associated with EMT and STAT3 activity [237]. The stemness factor 
SOX2 is upregulated by lncRNAs such as SOX2OT [238] and linc00617 [239]. Further, the 
self-renewal hedgehog (HH) pathway is activated by lncRNAs including lncRNA-Hh, which 
promotes CSCs maintenance through the activation of the HH-GLI1-SOX2 axis [240].
4.3.4. LncRNAs and drug resistance in breast cancer
The lncRNA BCAR4 (breast cancer antiestrogen resistance 4) was identified from a screen 
designed to find mechanisms of estrogen resistance in breast cancer. Ectopic expression of BCAR4 
in tamoxifen-sensitive ZR-75-1 breast cancer cells inhibited the cancer cell death mediated by 
tamoxifen, thereby making BCAR4 an important biomarker for tamoxifen resistant breast cancer. 
Since BCAR4 expression has only been detected in human placenta apart from breast cancer epi-
thelia, silencing of BCAR4 in breast cancer patients could be a potential anticancer therapy due to 
the limited number of side effects of diminishing BCAR4 expression in other healthy tissues [241].
Trastuzumab resistance is a major impediment in the clinical management of HER2-positive 
breast cancer. LncRNA GAS5 is downregulated in trastuzumab-treated breast cancer patient 
specimens, breast tumors in animal model in vivo and trastuzumab resistant breast cancer 
cell line, SKBR-3/Tr in vitro. GAS5 targets miR-21, resulting in a restoration of the levels 
of the miR-21 target, PTEN. Since PTEN is a tumor suppressor affecting cell proliferation, 
reactivation of this gene results in cell cycle arrest in breast cancer cells [242]. This identifies 
GAS5 as a novel prognostic marker and potential therapeutic target for HER-2 positive breast 
cancer. Also, GAS5 levels are significantly downregulated in TNBC cell line MDA-MB-231. 
Restoration of GAS5 levels in MDA-MB-231 sensitizes these cells to UV-C irradiation induced 
cell death. PI3K and mTOR inhibition could restore GAS5 levels [243]. Thus, reactivation of 
GAS5 using PI3K/mTOR inhibitors in TNBC may be a therapeutic option to sensitize this 
aggressive cancer to chemotherapy.
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4.3.5. LncRNAs for breast cancer prognosis, diagnosis and therapy
LncRNAs are being evaluated to have potential as breast cancer biomarkers, for breast cancer 
subtype classification and developing diagnostics and therapies, owing to their cell-type spe-
cific expression and correlation with patient response to chemotherapy. In a recent study, more 
than 1300 lncRNAs and 2800 mRNAs were found to be enriched in HER-2-enriched subtype 
breast cancer as compared to normal tissue. AFAP1-AS1 was identified as the most dysregu-
lated lncRNA, whereas lncRNA LOC100288637 displayed the highest positive correlation with 
HER-2 expression indicating the potential use of these lncRNAs as breast cancer biomarkers 
[244]. Furthermore, a transcriptomic analysis of triple negative (TN) breast cancer samples as 
compared to control identified a unique mRNA-lncRNA signature. The authors demonstrated 
that HIF1A-AS2 and AK124454 promoted cell proliferation and invasion in TNBC cells and 
contributed to paclitaxel resistance [245]. Such studies and many more in the future will help 
identify novel lncRNA biomarkers for breast cancer classification and disease progression.
Similar to miRNAs, circulating lncRNAs have been detected in plasma of cancer patients 
[246]. Recently, increased expression of lncRNA RP11-445H22.4 was detected in the plasma 
of breast cancer patients as compared to healthy individuals [247]. Further, HOTAIR DNA 
has been established as a potential biomarker for breast cancer as these patients displayed an 
upregulated expression of HOTAIR DNA as compared to healthy individuals. Moreover, the 
expression level of HOTAIR DNA correlated with the progress of the cancer [248].
In conclusion, noncoding RNAs including miRNAs and lncRNAs represent a significant 
resource of novel cancer biomarkers including noninvasive circulating noncoding RNAs, 
prognostic aids and potential therapeutic targets to be used in conjunction with chemo-
therapy and adjuvant therapy. However, significant research is required, especially in the 
lncRNA field, to take these RNA molecules from the bench to bedside.
5. Conclusion
In summary, due to the advances in sequencing techniques and novel methods to study chroma-
tin organization, the repertoire of information about the significant role played by the chromatin 
architecture, and its dysregulation in cancer cells is slowly being uncovered. The knowledge 
that the epigenetic landscape shapes the underlying genetic information is revolutionizing the 
field of cancer biology, the organized chaos in the genome of cancer cells now can be attributed 
at least in part to the aberrant regulation of chromatin modifiers and remodelers. The way in 
which cell-signaling pathways interact with epigenetic elements in the genome appears to be 
wide spread and complex. Integrating both networks is important not only for the comprehen-
sion of complex processes such as development, cell differentiation, cell regulation and cell plas-
ticity but also toward the study of the relationship between signal transduction pathways and 
its targeted effect over diverse epigenetic processes. The therapeutic implication of targeting 
the epigenetic regulators has been discussed in detail and is the focus of many ongoing clinical 
trials as well as research. An integrative research platform will help in curating the information 
and translating the current epigenetic discoveries into useful diagnostic and therapeutic tools.
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Appendix
Abbreviation used Full form
5caC 5-carboxylcytosine
5fC 5-formylcytosine
5hmC 5-hydroxymethylcytosine
AE Antiestrogens
AI Aromatase inhibitor
AIB1 Amplified in breast cancer 1
AKT1 AKT8 virus oncogene cellular homolog
AMO Anti-miRNA oligonucleotides
APC Adenomatous polyposis coli
ARID1A/ARID1B AT-rich interactive domain-containing protein 1 A/B
ASOs Antisense oligonucleotides
ATP Adenosine triphosphate
Aza 5-aza-2′-deoxycytidine
BAF155/SMARCC1 BRG1-associated Factor 155/SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin subfamily C member 1
BCAP31 B-cell receptor-associated protein 31
BCAR4 Breast cancer antiestrogen resistance 4
Bcl-2 B-Cell CLL/Lymphoma 2
BMI1 B lymphoma Mo-MLV insertion region 1 homolog
BRCA1 Breast cancer gene 1
BRG1 Brahma-related gene 1
BRM Brahma
BRMS1 Breast cancer metastasis suppressor 1
CARM1 Coactivator associated arginine methyltransferase 1
CBP Cyclic amp response element binding protein
CD44 Cluster of differentiation 44
CDH1 E-cadherin
cDNA Complimentary deoxyribonucleic acid
CHD Chromodomain helicase DNA-binding
ChIP Chromatin Immunoprecipitation
CK5/CK14 Cytokeratin-5/14
CoREST RE1-silencing transcription factor corepressor complex
CpG Cytosine preceding Guanine
CSC Cancer stem cells
CYP19A1 Cytochrome P450 family 19 subfamily A member 1
DNA Deoxyribonucleic acid
DNMT DNA methyltransferase
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Abbreviation used Full form
E2F1 Transcription factor activating adenovirus E2 gene
EED Embryonic ectoderm development
EGFR Epidermal growth factor receptor
ELF5 E74-like ETS transcription factor 5
EMT Epithelial mesenchymal transition
ER Estrogen receptor
ERBB2 Erb-B2 receptor tyrosine kinase 2
ERE Estrogen-responsive elements
ERK1/2 Extracellular signal-regulated protein kinase 1/2
EZH2 Enhancer of zeste 2
FFPE Formalin-fixed paraffin-embedded
FOXC1 Forkhead Box C1
GAS5 Growth Arrest Specific 5
GATA Transcription factors that can bind to the DNA sequence  
(A/T)GATA(A/G).
GATA3 GATA binding protein 3
GLI1 Glioma-associated oncogene homolog 1 (Zinc Finger Protein)
GSK3B Glycogen synthase kinase 3 Beta
HAT Histone acetyltransferases
HDAC Histone deacetylases
HER2 Human epidermal growth factor receptor 2
HH Hedgehog
HMGA2 High mobility group AT-hook2
HMT Histone methyl transferase
hnRNP I Heterogeneous nuclear ribonucleoprotein I
HOXA Homeobox A
HP1 Heterochromatin Protein 1
HRE Hormone-responsive elements
IHC Immunohistochemistry
IL-6 Interleukin 6
IR Ionizing radiation
IRAK1 Interleukin 1 receptor-associated kinase 1
ISH In situ hybridization
ITBG3 Integrin β 3
JARID1C Jumonji, AT Rich Interactive Domain 1C
KDM/HDM Lysine/histone demethylase
KIT v-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog
LCOR Ligand-dependent corepressor
LNA Locked nucleic acid
lncRNAs Long noncoding RNAs
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Abbreviation used Full form
LNN Lymph node-negative
LSINCTs Long stress-induced noncoding transcripts
LZTS1 Leucine zipper, putative tumor suppressor 1
MAL MyD88-adapter-like
MALAT1 Metastasis associated lung adenocarcinoma transcript 1
MAPK Mitogen-activated protein kinases
MaSCs Mammary stem cells
MBD2/3 Methyl-CpG binding domain protein 2/3
MeCP2 Methyl-CpG binding protein 2
MEG3 Maternally expressed gene 3
miRNA microRNA
MMP Matrix metalloprotease
MOF Male absent on the first
MORF MOZ-related factor
MOZ Monocytic leukemic zinc finger
mRNA Messenger ribonucleic acid
MSK1 Mitogen and stress activated protein kinase 1
MTA Metastasis-associated proteins
mTOR Mammalian target of rapamycin
MYST Moz, Ybf1, Sas2, TIP60
NCOR Nuclear receptor corepressor
NEAT-1 Nuclear Paraspeckle Assembly Transcript 1
NFκB Nuclear factor κB
NKILA NF-κB interacting lncRNA
NOTCH1 Notch Homolog 1, translocation-associated
NSD3L Nuclear SET domain-containing protein 3 long isoform
NuRD Nucleosome remodeling and histone deacetylation
OHT Hydroxytamoxifen
ORM2 Orosomucoid 2
p27 Cyclin-dependent kinase inhibitor 1B (p27, KIP1)
PARP Poly (ADP-ribose) polymerase
PCAF p300/CBP-associated factor
PCDH10 Protocadherin 10
PCDHB5 Protocadherin Beta 5
PCR Polymerase chain reaction
PDCD4 Programmed cell death 4
PDXP Pyridoxal phosphate phosphatase
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Abbreviation used Full form
PEBP1 Phosphatidylethanolamine binding protein 1
PELP1 Proline, glutamate and leucine-rich protein 1
PI3K Phosphoinositide 3 kinase
piRNA piwi-interacting RNA
Piwi P-element induced WImpy testis in Drosophila
PKB Protein kinase B
PKC Protein kinase C
PNA Peptide Nucleic Acids
PP1 Phosphoprotein phosphatase 1
PP2A Phosphoprotein phosphatase 2A
PR Progesterone receptor
PRC2 Polycomb repressive complex 2
pS2 Gene which codes for Trefoil factor 1 (TFF1)
PSPC1 Paraspeckle component 1
PTEN Phosphatase and tensin homolog
RARβ Retinoic acid receptor beta
RASSF1A Ras association domain family member 1
RB1 Retinoblastoma 1
REA Repressor of estrogen receptor activity
RNA Ribonucleic acid
RUNX3 Runt related transcription factor 3
S6K1 Ribosomal protein S6 kinase beta-1
SAHA Suberoylanilide hydroxamic acid
SAM S-adenosyl methionine
SET domain Suppressor of variegation 3-9 (Su(var)3-9), enhancer of zeste (E(z)), and trithorax 
(Trx) domain
SFRP1 Secreted frizzled-related protein 1
SHR Steroid hormone receptors
siRNA Small interfering RNA
SMARCD1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily D, member 1
SMRT Silencing mediator of retinoid and thyroid hormone receptors
SOX-2 SRY (sex determining region Y)-box 2
SRA Steroid receptor RNA activator protein
Src Rous sarcoma oncogene cellular homolog
SRC Steroid receptor coactivator
Suz12 Suppressor of zeste 12 protein homolog
SWI/SNF Switch/sucrose nonfermentable
TET Ten-eleven translocation
TGF-β Transforming growth factor β
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